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ABSTRACT
Insulin resistance in type 2 diabetes is associated with impaired glucose and
protein metabolism in skeletal muscle. The impaired insulin signaling in skeletal muscle
affects muscle mass by tilting the balance between skeletal muscle protein synthesis and
degradation toward degradation, a process that is primarily regulated by the ubiquitinproteasome system. Studies have shown that an extensively characterized ethanol extract of
Artemisia dracunculus L (Russian Tarragon), termed PMI 5011, enhances insulin signaling
in human primary skeletal muscle cells and in a rodent model of insulin resistance. The
aim of this project is to determine if the effect of PMI 5011 on insulin signaling extends to
regulation of ubiquitin-proteasome activity in skeletal muscle. To evaluate the effect of PMI
5011 on the ubiquitin-proteasome system, we used two in vitro models of insulin resistance
in C2C12 myotubes and the KKAy mouse model of insulin resistance in vivo. Our studies
show that PMI 5011 enhances the inhibitory effect of insulin on proteasome activity and
ubiquitylation in skeletal muscle in vitro and in vivo. In addition, PMI 5011 inhibits nonproteasomal protein degradation in vivo, indicating that PMI 5011 is a potent inhibitor of
skeletal muscle protein degradation. PMI 5011 also regulates the expression of Atrogin-1
and MuRF-1, muscle-specific ubiquitin ligases that are required for ubiquitin-dependent
protein degradation in skeletal muscle. Both Atrogin-1 and MuRF-1 gene and protein
expression is elevated with impaired insulin signaling and our studies show that PMI 5011
reduces the expression of these ligases while enhancing Akt phosphorylation. In summary,
these studies demonstrate that PMI 5011 regulates the ubiquitin-proteasome in insulin
resistant states in vitro and in vivo. PMI 5011 may therefore be a therapeutic target for
enhancing insulin sensitivity leading to conservation of muscle mass in type 2 diabetes.
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CHAPTER 1. INTRODUCTION

1.1 Discovery and Use of Medicinal Plants from NTFPs and PMI 5011
Natural drugs from traditional medicines are gaining popularity due to fewer side
effects, reduced cost, and increased patient use (Phillipson, 2001). NTFPs are those
plants or plant parts found within the forest that are not considered for use as timber.
They include mushrooms, edible fruits and berries, leaves, roots, and bark utilized for
herbal medicines, as well as wood for carving, twigs for decorative baskets or wreaths
and many others. From these NTFPs, herbal medicines derived from forest products
constitute the highest valued segment of the NTFP industry (Chamberlain and Hammett,
1998). It is also thought that NTFPs contribute to sustainable forest management,
conservation and to economic and development objectives (Panayotou and Ashton, 1992).
According to the World Health Organization (WHO) traditional and herbal medicines are
used throughout the world and constitute 70-95% of the primary therapeutic agents in
developing countries. They estimate that the global market for herbal medicines in U.S.
currency annually as of 2008 is $83 billion with an expected exponential increase (WHO,
2011). There is evidence in the fossil record that humans have been utilizing plants for
medicinal purposes as far back as 60,000 years ago (Solecki, 1975). In the United States,
the earliest recorded use of herbal medicines by Native Americans occurred in the 1600’s.
These herbal medicines were passed on to American settlers who also used the medicinal
remedies brought from their own countries. These herbal medicines were used until the
early 1900’s when the synthesis of natural product substitutes first began. At that time,
there was a major shift from natural plant remedies to synthetic drugs and over the next

century the Federal government became involved by enacting several Amendments and
Acts to regulate both herbal medicines and synthetic drugs used in America (Rates, 2001).
Since the 1990’s there has be a resurgence of interest in naturally derived medicines. Of
the top 20 prescriptions in 1996, six were natural products (Phillipson, 2001). During the
1990’s, medical research on such drugs as taxol from the Pacific yew, etoposide from the
American mayapple and artemisinin from annual wormwood helped increase an interest
and demand for botanical sources of medicinal drugs thereby increasing the demand for
non-timber forestry products (Chamberlain and Hammett, 1998). “Natural products have
contributed nearly half of all small molecules approved in the past decade” (Patwardhan
and Mashelkar, 2009). The number of higher plant species on this planet is listed at
500,000 and of these, 6% has been screened for biological activity and only 15% has
been phytochemically tested (Verpoorte, R. 2000). In biomedical research, the goal of
using medicinal plants as a source of therapeutic agents is to target the isolation of the
bioactive compounds for synthesis and direct use as drugs and to use compounds as
pharmacologic tools or as an herbal remedy. The process usually starts with previous
knowledge of a particular plant that has been recorded in history followed by biological
and toxicological assays for activities of interest. The process may also include random
collection and selection of plant materials followed by phytochemical screening
approaches for selection of specific secondary plant metabolites such as flavonoids,
alkaloids, etc. (Farnsworth, 1966). This selection is then followed by biological and
toxicological assay assessment, most commonly by in vitro assays followed by in vivo
assessment (Fabricant and Farnsworth, 2001). This process then leads to further
fractionation and isolation of pure compounds through numerous extraction techniques
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including cold extraction, hot percolation, supercritical fluid extraction or soxhlet
extraction followed by chemical characterization with chromatography, (TLC, HPLC,
HRMS, HPCC, and SEC) NMR, CZE, X-ray analysis or Mass Spectrometry (HRMS)
that leads to synthesis of the active components (Gurib-Fakin, 2006 and Borris, 1996).
This process is summarized below in Figure 1.1.

Figure 1.1. Method for biological and toxicological assay guided active compound
selection.
Adapted from Rates (2001).
In this way, drugs have been discovered and are now commonly used. To date, some
hundred or so drugs have been developed from medicinal plants. An abbreviated list of
some examples of these drugs discovered from plants is listed in Table 1.
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Table 1. Drugs derived from plant sources.
Drug	
  
Action	
  
Plant	
  Source	
  
Acetyldigoxin	
  
Cardiotonic	
  
Digitalis	
  lanatat	
  Ehrh.	
  
Anisodine	
  
Anticholinergic	
  
Anisodus	
  tanguticus	
  Pascher	
  
Atropine	
  
Anticholinergic	
  
Atropa	
  belladonna	
  L.	
  
Berberine	
  
Bacillary	
  dysentery	
  
Berberis	
  vulgaris	
  L.	
  
Caffeine	
  
CNS	
  stimulant	
  
Camellia	
  sinensis	
  (L.)	
  Kuntz	
  
Camphor*	
  
Antimicrobial	
  
Cinnamonum	
  camphora	
  L.	
  
Camptothecin*	
  
Anticancer	
  
Camptotheca	
  acuminata	
  Decne.	
  
Codeine	
  
Analgesic;	
  antitussive	
  
Papaver	
  somniferum	
  L.	
  
Curcumin	
  
Choleretic	
  
Curcuma	
  longa	
  L.	
  
Digitalin,	
  Digitoxin	
   Cardiotonic	
  
Digitalis	
  purpurea	
  L.	
  
Ephedrine	
  
Sympathomimetic	
  
Ephedra	
  sinica	
  Stapf.	
  
Etoposide	
  
Antitumour	
  agent	
  
Podophyllum	
  peltatum	
  L.	
  
Gossypol	
  
Male	
  Contraceptive	
  
Gossypium	
  spp.	
  
Kawain	
  
Tranquilizer	
  
Piper	
  methysicum	
  Forst.	
  f.	
  
Khellin	
  
Bronchodilator	
  
Ammi	
  visnaga	
  (L.)	
  Lamk.	
  
Metformin	
  
Antidiabetic	
  
Galega	
  officinalis	
  L.	
  
Morphine	
  
Analgesic	
  
Papaver	
  somniferum	
  L.	
  
Physostigmine	
  
Cholinesterase	
  inhibitor	
  
Physostigma	
  venenosum	
  Balf.	
  
Pseudoephedrine	
   Sympathomimetic	
  
Ephedra	
  sinica	
  Stapf.	
  
Quinine	
  
Antimalarial	
  
Cinchona	
  ledgeriana	
  Moens.	
  
Rhomitoxin	
  
Antihypertensive	
  
Rhododendron	
  molle	
  G.	
  Don	
  
Salicin	
  
Analgesic;	
  Anti-‐inflammatory	
   Salix	
  alba	
  L.	
  
Santonin	
  
Ascaricide	
  
Artemesia	
  maritima	
  L.	
  
Scopolamine	
  
Sedative	
  
Datura	
  metel	
  L.	
  
Taxol*	
  
Anticancer	
  
Taxus	
  brevifolia	
  Nutt.	
  
Thymol*	
  
Antiseptic	
  
Thymus	
  vulgaris	
  L.	
  
Tubocurarine	
  
Muscle	
  Relaxant	
  
Chondodendron	
  tomentosum	
  R.	
  &	
  P.	
  
Vinblastine*	
  
Anticancer	
  
Catharanthus	
  roseus	
  (L.)	
  G.	
  Don	
  
Xanthotoxin	
  
Leukoderma;	
  vitiligo	
  
Ammi	
  majus	
  L.	
  
Data adapted from Fabricant (2001) * Drugs discovered in random selection by the NCI
and CDRI
1.2 Diabetes Prevalence, Causes, and Treatment
Diabetes mellitus is a metabolic disease characterized by high blood glucose.
There are three main types of diabetes: type 1 diabetes that results from the body’s
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inability to produce insulin and is considered insulin-dependent diabetes; type 2 diabetes
that results from the development of resistance to the body’s own insulin supply, often
caused by obesity; and gestational diabetes that occurs during pregnancy that can proceed
the development of type 2 diabetes later in life (Expert Committee Report on the
Diagnosis and Classification of Diabetes Mellitus, 2002). The high blood glucose
associated with type 2 diabetes is a result of the body’s impaired response by peripheral
tissues to insulin. The reduction in the cellular uptake of glucose due to this insulin
resistance leads to the high blood glucose levels that are characteristic of type 2 diabetes.
This decreased cellular response to insulin or perturbation of the insulin signaling
pathways are associated with a number of pathological states (Taylor, 1992), including
cardiovascular diseases such as atherosclerosis and hypertension (Savage, et al., 2005;
Reaven, 2003). Diabetes is the seventh leading cause of death in the United States (Wild,
et al, 2004). According to the Centers for Disease Control, diabetes affects over 26
million Americans with 79 million having pre-diabetes defined as having fasting blood
glucose levels of 110 to 125 mg/dL (WHO criteria) or 100 to 125 mg/dL (ADA criteria).
According to the American Heart Association (American Heart Association, 2008),
diabetes contributes to about 225,000 U.S. deaths per year.
1.3 Insulin Resistance and Muscle Atrophy
In states of insulin resistance such as type 2 diabetes, both glucose and protein
metabolism are altered (Park, 2009). In the body, skeletal muscle is both the primary
storage site for proteins and the major site of glucose disposal. Approximately 80% of
insulin-stimulated glucose disposal occurs in skeletal muscle. Insulin plays a major role
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in regulating muscle protein metabolism, and its action in skeletal muscle helps to
maintain the balance between protein synthesis and degradation. Insulin stimulates
protein synthesis by activating transcription and by increasing tissue and cellular capacity
for protein synthesis (Proud, 2006). At the same time, insulin also inhibits protein
degradation by downregulating proteasome activity and the transcription of enzymes in
the ubiquitin system (Sacheck, et al., 2004). On the other hand, insulin resistance leads
to an imbalance between protein synthesis and breakdown in skeletal muscle, resulting in
structural and functional modifications of skeletal muscle proteins and the loss of muscle
mass. Recently, specific actions of insulin on various muscle proteins was shown to play
a major role in regulating muscle protein metabolism, and the dysregulation of insulin
action is thought to contribute to muscle wasting, also referred to as muscle atrophy
(Guillet and Boirie, 2005). Studies show that skeletal muscle atrophy occurs in response
to a number of catabolic conditions, such as fasting and several diseases such as AIDS,
sepsis, cancer, Cushing’s syndrome, and diabetes mellitus (Sandri, et al., 2004, Glass,
2003, Wang, et al., 2006 and Lecker, et al., 2004). In older, sedentary individuals,
especially women, there is a significant loss of muscle mass due to skeletal muscle
protein breakdown caused by the insulin resistance of type 2 diabetes (Wang, et al., 2006;
Price, et al., 1996; Mitch, et al., 1999). This insulin resistance leads to a decrease in lean
body mass and physical disabilities, including sarcopenia, that are associated with
morbidity and mortality (Wang, et al., 2006).
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A. Dexamethasone-Induced Insulin Resistance
The hormone cortisol is secreted from the adrenal cortex in response to
inflammation, pain, infection and stress (Newton, 2000).

It is called a glucocorticoid

because it is essential for long-term blood glucose maintenance (Champe and Harvey,
1994) and is a counter-regulatory hormone due to its opposing actions on insulinmediated metabolic functions. Cortisol opposes insulin’s actions by decreasing glucose
uptake into cells and decreasing insulin secretion by pancreatic β-cells. Cortisol affects
peripheral glucose metabolism by interrupting insulin-stimulated glucose uptake,
including insulin receptor binding (Olefsky et al., 1975 and Buren et al., 2002). These
actions can lead to hyperinsulinemia, hyperglycemia and insulin resistance (Rizza et al.,
1982; Andrew and Walker, 1999: and Newton 2000).

Glucocorticoids such as

dexamethasone decrease the rate of protein synthesis and increase the rate of protein
breakdown causing atrophy of skeletal muscle that is under the regulation of insulin and
insulin-like growth factor-I (IGF-I) (Goldberg, et al., 1980 and Lofberg et al., 2002).
Therefore, in insulin resistant states such as those induced by glucocorticoids, muscle
atrophy is upregulated. The glucocorticoid-induced protein degradation is due to
activation of the ubiquitin-proteasome system (Menconi, et al., 2008; Tiao, et al., 1996;
Schakman, et al., 2008). Administration of the synthetic glucocorticoid, dexamethasone
(DEX), results in increased expression of the two muscle specific E3 ubiquitin ligases
Atrogin-1 and MuRF-1, (Menconi, et al., 2008; Sandri, et al., 2004; Stitt, et al., 2004)
whose activity leads to muscle atrophy. The Dex-induced increase in Atrogin-1 and
MuRF-1 expression is dependent upon ligand binding to the glucocorticoid receptor
(Zhao, et al., 2009) leading to the activation of the transcription factors FoxO1and
7

FoxO3a that in turn upregulate the expression of Atrogin-1 (Sandri, et al., 2004; Skurk, et
al., 2004) and MuRF-1 (Waddell, et al., 2004).
B. Free Fatty Acid-Induced Model of Insulin Resistance In vitro.
Free Fatty Acid (FFA) deposition that occurs in insulin-sensitive tissues such as
the liver, pancreas and skeletal muscle (Jensen, 2006) causes systemic insulin resistance.
In obesity-related type 2 diabetes there is an associated increase in circulating plasma free
fatty acid (FFA) levels (Boden, 2006). First described by Randle in 1963, the
contribution of circulating plasma FFAs to the insulin resistance associated with type 2
diabetes is now well established. Their work carried out in rat heart and diaphragm
muscles originally focused on the effect of FFA on glycolysis (Randle, 1963). Later
efforts demonstrated that FFAs inhibit insulin’s action by inhibiting intracellular
pathways of glucose metabolism at the level of glucose transport and PI3K signaling
pathway (Dresner, 1999). FFA-induced insulin resistance occurs predominately in
skeletal muscle to a greater extent than in either the liver or endothelial cells (Boden,
2006). This can be observed within 2-4 hours of an increase in plasma FFA. A person
with a rise in plasma FFA from 400 to 800 pM after a fatty meal displays a reduction in
the effect of insulin by 50% (Boden, 2007). A gradual increase in triglycerides,
diacylglycerol (DAG) and the long chain acyl-CoA within muscle cells caused by
elevated FFAs is thought to be the underlying cause of insulin resistance in skeletal
muscle. This accumulation leads to inhibition of PI3K activation of Akt, thereby
inhibiting insulin signaling on two levels. Chavez et al., 2005, showed that in C2C12
myotubes, free fatty acids (FFA) inhibited the insulin stimulation of Akt/PKB signaling
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that regulates glucose uptake in addition to protein synthesis and the transcriptional
regulation of both Atrogin-1 and MuRF-1 atrogenes involved in skeletal muscle atrophy.
1.4 Muscle Protein Degradation and the Ubiquitin-Proteasome Pathway
The skeletal muscle atrophy associated with type 2 diabetes and insulin resistance
is caused in part, by ubiquitin-mediated proteolysis and the expression of two genes
encoding ubiquitin ligases, MAFbx/Atrogin-1 and MuRF1, that is increased in muscle
atrophy (Glass, 2003) and contribute most significantly to muscle atrophy (LagirandCantaloube, et al., 2009). The ubiquitin-proteolytic pathway catalyzes the breakdown of
polypeptides and proteins in a process where multiple ubiquitin moieties are covalently
conjugated to amino groups on the targeted proteins, marking them for degradation by the
26S proteasome. This process involves three sequential enzymatic reactions performed
by three types of enzymes: E1, E2, and E3 (Medina, et al., 1995 and Herrmann, et al.,
2007). Ubiquitin is first activated by ubiquitin-activating enzyme E1, in an ATPdependent manner. Next, the ubiquitin molecule is then passed on to the second enzyme
of the complex, E2 ubiquitin-conjugating enzyme. Next, it is recognized by the final
enzyme, E3, the ubiquitin protein ligase that binds the target substrate and labels it with
ubiquitin. The process can be repeated until a short chain is formed, with three or more
ubiquitin molecules targeting proteins for degradation at the proteasome (Wing, 2005).
The expression of the ubiquitin ligases Atrogin-1 and MuRF-1 is increased in all forms of
catabolic diseases that lead to muscle loss (Foletta, 2011). One potential proteolytic
trigger of skeletal muscle protein breakdown is a decrease in the response to insulin or
Insulin-like growth factor 1 (IGF-1) (Wang, et al., 2006). Impaired insulin signaling via
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the PI3K/AKT signaling cascade causes an imbalance between protein synthesis and
degradation that favors degradation of proteins in skeletal muscle (McKinnell and
Rudnicki, 2004). Loss of skeletal muscle mass and function is the result of prolonged
and accelerated protein degradation associated with insulin resistance (Mitch and
Goldberg, 1996). Insulin binds to the insulin receptor tyrosine kinase and initiates the
phosphatidylinositol 3-kinase/Akt (PI3K/AKT) signaling pathway that plays a major role
in metabolism, cell growth and proliferation (Glass, 2003 and 2010). Insulin-dependent
activation of phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB/AKT)
leads to a phosphorylation cascade affecting several downstream targets, including
FoxO3a gene expression (Proud, 2006, Schakman, et al., 2008, Sandri, et al., 2004, Zhao,
et al., 2007). Increased FoxO3a protein expression activates transcription of Atrogin-1
and MuRF1 (Schakman, et al., 2008). The IGF-1/PI3K/Akt pathway prevents the
expression of these two ubiquitin ligases by inhibiting FoxO transcription factors (Stitt, et
al., 2004). Phosphorylation of FoxO proteins leads to their exclusion from the nucleus
and inhibition of FoxO3a-mediated MuRF1 and Atrogin-1 gene expression, thereby
blocking ubiquitin-mediated muscle atrophy (Glass, 2010).
1.5 Treament of Insulin Resistance and Type 2 Diabetes
The American Diabetes Association makes the following recommends in their
Standards of Medical Care in Diabetes—2012 issue of Diabetes Care;
1.
2.
3.
4.
5.

Glucose monitoring daily
A1C testing annually
Lifestyle interventions - Diet and Exercise
Medical Nutrition Therapy
Pharmacological Interventions
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a) Insulin-Type I diabetes and in extreme cases of Type II and gestational
diabetes.
b) Biguanide Class - i.e. Metformin**
c) Sulfonylureas
d) Meglitinides
e) Thiazolidinediones (Glitazone)
f) α-glucoside inhibitors
g) GLP-1 receptor agonists (incretin mimatics)
h) DPP-4 inhibitors (incretin enhancers)
i) Bile acid sequestrants
j) Dopamine-2 agonist
6. Bariatric Surgery - in extreme cases.
**=Plant-based Diabetic Drugs.
Many of these interventions such as lifestyle changes in diet and exercise are not easily
achieved nor maintained over extended periods (Curioni and Lourenco, 2005 and Tate, et
al., 2007). In addition, dangerous surgeries such as bariatric surgery should be avoided at
all costs due to complications and expense. Lastly, pharmacological interventions have
provided a powerful tool in combating the complications of type 2 diabetes. Recently,
there has been a renewed interest in natural products in the treatment of several diseases
including type 2 diabetes.
1.6 Artemisia dracunculus L. (PMI 5011), Metformin and Diabetes.
Many plants have been described in both clinical research and traditional
medicine to have antidiabetic properties including improved glucose uptake and reduced
insulin resistance. Medicinal herbs have been used for antidiabetic properties and
contain herbal extracts that restore the function of pancreatic tissues and cause increased
insulin output by the functioning beta cells, while other ingredients enhance the
microcirculation, and increase the availability of insulin and facilitate metabolism in
insulin-dependent processes (Jia, 2003). Some examples of the most commonly used
plant based botanical products that have been studied and used for their antidiabetic
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properties are bitter melon (Momordica charantia), fenugreek (Trigonella foenumgraecum), gurmar (Gymnema sylvestre), ivy gourd (Coccinia indica), prickly pear cactus
(Optunia streptacantha), ginseng (Panax, sp.), aloe vera (Aloe barbadensis), garlic
(Allium sativum) and Russian tarragon (Artemisia dracunculus) (reviewed in Cefalu, et
al., 2008).
Many drugs in the past were originally derived from plants. One drug of particular
interest is metformin. Metformin was originally discovered from a plant source Galega
officinalis commonly known as goat’s rue or French lilac. Metformin is one of the most
commonly prescribed drugs in the treatment of type 2 diabetes and is often the first line
of defense chosen by physicians. Its original use can be traced to medieval times, when it
was used to relieve the frequent urination associated with diabetes mellitus (Witters,
2001). Metformin not only lowers blood glucose levels but it also inhibits adipose tissue
lipolysis, reduces circulating free fatty acids, and diminishes very low density lipoprotein
(VLDL) production (Wood, et al., 1996). The glucose-lowering effect of metformin is
caused by a combination of several distinct activities in various organs and tissues.
Among the known actions of metformin are an improvement of insulin sensitivity in both
the muscle and liver, a decrease in hepatic glucose production from gluconeogenesis, an
increase in peripheral glucose utilization through stimulation of insulin-mediated muscle
glucose uptake and glycogen synthesis as well as positive effects on insulin receptor
expression and tyrosine kinase activity (Cusi, et al., 1996 and Stepensky, et al., 2002).
Metformin is a clear example of the impact of plant-based drug discovery. A renewed
interest from the pharmaceutical industry and the general public in the use of plants as
medicinal therapies, as sources of new lead molecules and as conventional and
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complementary therapies has led to a recent and significant increase in research to
discover new botanical compounds for future drug development (Li, et al., 2004).
This dissertation focuses on Artemisia dracunculus L, the plant commonly
referred to as Russian tarragon. It is a perennial herb belonging to the Asteraceae family.
There are over 1500 species in the plant genus Artemisia, and it has been utilized for both
herbal remedies as well as conventional drugs. In addition to A. dracunculus, some
examples of the medicinal applications of Artemisia species include A. annua as a
malaria treatment, and three other Artemisia species used to treat diabetes are; A. herbaalba as a tea, A. pallens ethanolic extracts, and A. santonicum that are being used in
traditional medicine throughout the world (Ribnicky, et al., 2006). The ethanolic extract
of Artemisia dracunculus is termed PMI 5011. PMI 5011 was originally identified from
a screening of extracts for hypoglycemic activity in diabetic mice and was identified as
the most promising candidate for the development of a nutritional supplement for the
treatment of type 2 diabetes (Cefalu, et al., 2008). Studies have shown that PMI 5011
decreases circulating blood glucose and improves insulin levels in both in vivo and in
vitro models of type 2 diabetes (Ribnicky, 2006 & 2009, Wang, et al., 2008 & 2010, Kirk,
et al., 2008, Zuberi, 2008, and Obanda, et al., 2012). The extract enhances insulin
stimulated glucose uptake and increases the levels of insulin receptor substrate-2 (IRS-2)
in skeletal muscle cells of obese rats (Ribnicky, et al., 2006). The active compounds in
the extract are polyphenols that are members of the sesquiterpene lactone and flavonoid
groups, of which the Artemisia family is well known (Ribnicky, et al., 2006).

Current

data further suggests that PMI-5011 may improve carbohydrate metabolism by enhancing
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the molecular actions of insulin in skeletal muscle (Ribnicky, et al., 2006, Cefalu, et al.,
2008, Wang, et al., 2008 & 2010 and Obanda, et al., 2012).
1.7 Polyphenols, Carbohydrate Metabolism, and Diabetes
Polyphenols are a structural class of organic chemicals mainly found in nature
that are characterized by their multiple phenol structural groups. Plants mainly
synthesize polyphenols in addition to certain fungi and a few animals. Polyphenols are
protective chemicals in plants and provide a defense against predators/infections, defense
against sunlight damage and chemical oxidation, and they provide coloration (Guyente,
2011). The color of many fruits and vegetables, such as blueberries, eggplants, grapes
and apples comes from polyphenols. The number of phenol groups and characteristics of
these structures give them their unique physical, chemical, and biological (metabolic,
toxic, therapeutic, etc.) properties. The four main classes are the phenolic acids,
flavonoids, lignans and stilbenes. Polyphenols are mainly known for their antioxidant
properties and have been studied in implications as preventatives for oxidative-related
diseases such as hypertension, diabetes and cardiovascular disease (CVD) (Manach, et al.,
2004). The structural diversity of the polyphenols provides differences in biological
activities and bioavailability (Scalbert and Williamson, 2000 and Manach, et al., 2004).
Phenolic acids containing only one phenol ring are the most basic of the polyphenols and
the most commonly found in nature. The flavonoids contain 2 aromatic rings linked
together by oxygenated heterocycle consisting of 3 carbon atoms and are classified
further into 6 subclasses: flavanols, flavones, flavanones, isoflavones, anthocyanidines
and flavanols (catechins and proanthocyanidins). Lignans are dimeric compounds that
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contain two phenylpropane units connected by a central carbon of their side chains.
Lastly, the stilbenes are isomeric hydrocarbons and are the least common. Resveratrol is
the most popular of stilbenes studied (Manach, et al, 2004).
Chalcones are flavonoids lacking a heterocyclic C ring (Calliste et al., 2001) and
are α-β-unsaturated ketones that have been shown to have anti-inflammatory, anticancer,
antiviral, antiprotozoal, antibacterial, antifungal and insecticidal activities as well as
having enzyme-inhibitory activities (Dimmock, et al., 1999). The anti-hyperglycemic
active components found in PMI 5011 are 6-demethoxycapillarisin and 2’, 4’ dihydroxy4-methoxydihydrochalcone (Govorko, et al., 2007). 2’, 4’ dihydroxy-4methoxydihydrochalcone (DMC) is a chalcone and plant stress compound described as a
de novo metabolite of stressed plants (Carlson and Dolphin, 1981).
1.8 Medicinal Plants and the Ubiquitin Proteasome
The ubiquitin-proteasome pathway is responsible for energy-dependent protein
degradation and is involved in many cellular processes such as cell-cycle regulation,
transcription, proliferation, apoptosis and angiogenesis. Studies show that cancer cells
are more susceptible to proteasome inhibition than normal cells (Yang, et al., 2008).
Therefore, proteasome inhibitors have been targeted as anticancer drugs targets. There
are several types of proteasome inhibitors including peptide aldehydes (MG132, MG115,
and LLnL), peptide boronate, peptide vinyl sulfone, peptide epoxyketone, and naturally
derived sources (Screen, et al., 2010). To date, the peptide aldehydes are the most
understood and utilized proteasome inhibitors. One of the first proteasomal inhibitors
was isolated from a natural compound in the 1990’s called lactacystin and it was
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originally discovered in microbial Streptomyces. Other natural product proteasomal
inhibitors include the polyphenol EGCG derived from green tea (Camellia sinensis),
several polyphenol flavonoids including resveratrol, apigenin, and quercetin from grape
extracts, polyphenol isoflavones called genistein from soy, polyphenol flavonoids from
turmeric called curcumin, quione methide tripterene called celastrol from the
Tripterygium wilfordii and a methyl ester of celastrol from Celastraceae family called
pristimerin. All have been found to block chymotrypsin-like activity of the proteasome
(Yang, et al., 2008; Chen, et al., 2011). Possibly the most studied natural product
proteasome inhibitor of late is the green tea polyphenol known as (-)-epigallocatechin
gallate [(-)-EGCG] that has been shown to inhibit proteasomal activity in cancer cells.
However, much like other natural products it has been found unstable under
physiological conditions. Dou et al. developed a peracetate-protected or pro-drug form
of (-) EGCG termed Pro-EGCG that increases the stability and bioavailability, thereby
improving the proteasome-inhibitory and anticancer activities (Dou et al., 2008).
Recently, Alamadari, et al. reported on the polyphenol resveratrol (3,5,4’trihydroxystilbene) and its inhibition of dexamethasone-induced expression of the two E3
ubiquitin ligases Atrogin-1 and MuRF-1. Their studies in vitro in murine L6 myotubes
showed that glucocorticoid induced atrophy were blocked with treatment of resveratrol in
a SIRT1 dependent manner (Alamadari, et al., 2012). Other studies on resveratrol have
provided evidence for the muscle sparing effects provided by this compound in diseases
that are associated with muscle wasting such as diabetes, muscular dystrophy, muscle
disuse and cancer (Alamadari, et al., 2012). Natural compounds such as resveratrol and
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those active components of the extract of Artemesia dracunculus have important clinical
implications for therapeutic uses for muscle atrophy associated with disease.
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CHAPTER 2: EXPERIMENTAL PROCEDURES
2.1 PMI 5011 Extract Preparation
The PMI 5011 botanical extract from Artemisia dracunculus L. was provided by
the Botanical Centers at Rutgers University and Pennington Biomedical Research Center.
Detailed information about quality control, preparation, and biochemical characterization
of PMI 5011 has been previously reported (Ribnicky, et al., 2005). In brief, the seeds of
Artemesia dracunculus L. were purchased from Sheffield’s Seed Co. Inc. (Locke, NY).
Plants were grown hydroponically in greenhouses under uniform and strictly controlled
conditions, thereby standardizing the plants for their phytochemical content. Total plants
were harvested above the root mass, frozen and stored at -20º C prior to extraction
through ethanolic preparations. The extract has been extensively characterized through
the isolation of active components by activity-guided fractionation using in vitro
bioassays followed by confirmation in vivo (Ribnicky, et al., 2005). Purification,
isolation and identification were achieved with high performance liquid chromatography
(HPLC) analysis and liquid chromatography-mass spectrometry (LCMS) analysis. For
further detail on complete experimental procedures, please refer to Ribnicky, et al., 2005.
2.2 Cell Culture
C2C12 cells are derived from myoblast cells isolated from the thigh muscle of
two-month-old C3H mice (Yaffe and Saxel, 1977). C2C12 cells are a diploid subclone
selected for their ability to differentiate rapidly and produce extensive contracting
myotubes that express characteristic muscle proteins (Blau, et al., 1985). The C2C12
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cells are differentiated into myotubes by transferring the cells from 10% fetal bovine
serum to 2% horse serum once they have reached confluence. These cells are commonly
used as a tool to study skeletal muscle protein and gene expression, differentiation of
myoblasts and the mechanistic pathways related to skeletal muscle biology. C2C12
murine myoblasts were obtained from ATCC and grown in complete growth medium of
Dulbecco’s Modified Eagle’s Medium, 1g/L glucose without sodium pyruvate (DMEMCellgro), but with L-glutamine, 10% fetal bovine serum (HyClone) and 1% PenicillinStreptomycin (MP Biomedicals). Cells are grown to sub-confluence at 37°C at 5% CO2.
To induce myotubes formation, cells are allowed to become confluent and then
supplemented with 2% horse serum (HyClone) in place of fetal bovine serum and grown
at 37°C at 5% CO2. C2C12 myotubes 6-9 days post-induction were used for all
experiments in vitro. C2C12 myotubes were preincubated with PMI 5011 (10 µg/ml) for
16 hours prior to the addition of wortmannin (200 nM) for PI3K signaling assays. To
induce insulin resistance, differentiated myotubes were treated with the glucocorticoid
dexamethasone at 1µM concentration for 24 hours. Cells were also incubated in the
absence or presence of the botanical extract PMI 5011 at 10µg/ml overnight. As another
model of insulin resistance in vitro, differentiated C2C12 myotubes were treated with the
free fatty acid palmitic acid at 200 µM overnight with and without 10µg/ml of PMI 5011.
Both insulin resistance models are discussed in detail below.
2.3 Induction of Insulin Resistance
1. Dexamethasone Treatment. C2C12 myotubes were initially incubated in the absence
or presence of dexamethasone (1 µM) (Sigma Aldrich, St. Louis, MO) for 24 hours.
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Subsequent experiments were carried out in the absence or presence of dexamethasone
and PMI 5011 (10 µg/ml) for 24 hours. When added, PMI 5011 was present for 4 hours
prior to the addition of dexamethasone. Twenty four hours after adding dexamethasone,
the cells were harvested for isolation of RNA and whole cell extracts.

2. Free Fatty Acid Treatment. Palmitic acid (Sigma Aldrich, St. Louis, MO) was diluted
in ethanol at 100 mM and further diluted to a 6 mM working solution in 2% fatty acid
free Bovine Serum Albumin (BSA) in DMEM. The 6 mM solution was briefly sonicated
and incubated for 20 minutes at 55° C until a clear solution was observed. The palmitic
acid was then diluted to the desired final concentration and sterile filtered. C2C12
myotubes were incubated in the absence or presence of palmitic acid (200 µM) and PMI
5011 (10 µg/ml) for 16 hours in DMEM, 10% FBS. Thereafter, the media was exchanged
for DMEM containing 0.3% fatty acid free BSA in the presence or absence of palmitic
acid and PMI 5011for 6 hours prior to insulin stimulation (100 nM insulin). Two hours
after adding insulin, the cells were harvested for isolation of RNA and whole cell extracts.
2.4 Preparation of Whole Cell Extracts
Skeletal muscle tissue lysates were prepared by dissecting the muscle free of
adipose tissue and homogenizing in 25 mM HEPES, pH 7.4, 1% Nonidet P-40 (NP-40),
137 mM NaCl, 1 mM PMSF, 10 µg/ml aprotinin, 1 µg/ml pepstatin, 5 µg/ml leupeptin
using a PRO 200 homogenizer (PRO Scientific, Inc., Oxford, CT). The samples were
centrifuged at 14,000×g for 20 min at 4°C. Whole cell extracts were harvested from the
C2C12 myotubes in a lysis buffer containing 50 mM Tris-Cl, pH 7.4 with 150 mM NaCl,
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1 mM EDTA, 1% Igepal, 0.5% Na-deoxycholate, 0.1% SDS, 10 mM N-EM, and protease
inhibitors (1 µM PMSF, 1 µM pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10
µM leupeptin) and lysed via sonication. In each case, protein concentrations were
determined using a BCA assay (Thermo Fisher Scientific, Rockford, IL) according to the
manufacturer's instructions. The tissue supernatants (50 µg) and C2C12 whole cell
extracts (50 µg) were resolved by SDS-PAGE and subjected to immunoblotting using
chemiluminescence detection (Thermo Fisher Scientific, Rockford, IL) and quantified.
2.5 Gel Electrophoresis and Immunoblotting
Proteins were separated in 10% polyacrylamide (acrylamide from National
Diagnostics) gels containing sodium dodecyl sulfate (SDS) according to Laemmli
(Laemmli, 1970) and then transferred to nitrocellulose membrane at 25 volts overnight at
4ºC in 25 mM Tris, 192 mM glycine, and 20% methanol. Membranes were blocked in
4% fat-free milk for 1 hour at room temperature before incubation in primary antibody
for 2-4 hours at room temperature at concentrations recommended by manufacturer.
Protein expression for Atrogin-1(ECM Biosciences), MuRF-1 (AbCam), ubiquitin (BD
Pharmingen), phosphorylated (S473) AKT (Cell Signaling), total AKT (Cell Signaling),
eIF3F (Bethyl), Foxo3a (Bethyl), phosphorylated (S253) Foxo3a (Millipore), mTOR and
phosphorylated (S2448) mTOR (Cell Signaling) and β-Actin (Bethyl) were determined
and compared to total protein content. Membranes were then exposed to the appropriate
secondary antibody at the concentration recommended by the manufacturer for 1 hour at
room temperature. Proteins were visualized with enhanced chemiluminescence (Pierce).
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2.6 RNA Isolation and Analysis
Total RNA was purified from the C2C12 cells using TriReagent (Molecular
Research Center) according to the manufacturer’s instructions. Total RNA was purified
from the skeletal muscle tissue using an RNeasy Fibrous Tissue Minikit (Qiagen)
according to the manufacturer’s directions. In each case, RNA (1 µg) was reverse
transcribed using Multiscribe Reverse Transcriptase (Applied Biosystems) with random
primers at 370C for 2 hours. Real-time PCR was performed with TaqMan two-step
chemistry with TaqMan primer/probe pairs using the 7900 Real-Time PCR system
(Applied Biosystems) and universal cycling conditions (50oC for 2 minutes; 95oC for 10
minutes; 40 cycles of 95oC for 15 seconds and 60 oC for 1 minute; followed by 95oC for
15 seconds, 60 oC for 15 seconds and 95oC for 15 seconds. Relative gene expression of
Atrogin-1, MuRF-1, 6S proteasome subunits PSMA5 and PSMB3, Ubiquitin B,
Ubiquitin C and Ubiquitin A52 were measured and compared to an endogenous
housekeeping gene (cyclophilin B). Samples were measured for quantitation of total
RNA content by the NanoDrop, UV-Vis instrument (Thermo Scientific).

2.7 Rodent Care

All animal studies were approved by the Institutional Animal Care and Use
Committee (IACUC) of Pennington Biomedical Research Center in accordance with
ALAC guidelines for the use of experimental animals. Six-week-old male KK-Ay mice
(n=16) purchased from the Jackson Laboratory (Bar Harbor, ME, USA) were single
housed in specific pathogen-free animal rooms maintained at 25°C with a 12-h light–dark
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cycle (8 a.m.–8 p.m.). The mice were maintained on a defined low-fat diet containing
16.4 kcal% protein, 10.5 kcal% fat, and 71.3 kcal% carbohydrate (D12329; Research
Diets, Inc., New Brunswick, NJ, USA). At 10 weeks of age, the mice were randomly
divided into a control group (N=8) and a PMI 5011-treated group (5011; n=8). The 5011
treatment group was fed ad libitum the same defined low-fat diet containing 1% (w/w) of
PMI 5011, whereas the control group was fed ad libitum D12329 diet only. PMI 5011
diet was prepared by making a fine powder of the defined low-fat diet with a Cuisinart
food processor. 1% (w/w) of PMI 5011 extract was then blended into the powder of lowfat diet. 100 mLs of water was added and the mixture was turned by hand and flattened
with a rolling pen in a large 1 gallon Ziploc bag. The bag was then scored into 1x1 cm
squares and placed in the -20ºC freezer. Mice were given squares of PMI 5011 diet from
-20ºC storage every other day when food was weighed and replaced to maintain the
freshness of the PMI 5011 diet.
2.8 Rodent Tissue Isolation
At the end of the study, both the control and PMI 5011 mice were further divided
into 2 groups (N=4) each. Insulin (1.5 U/kg intraperitoneal injection) was given to one
half of the mice (control, N=4; PMI 5011, N=4) and an equal volume of physiological
saline was administered to the remaining mice (control, N=4; PMI 5011, N=4). The mice
were euthanized ninety minutes post-injection and both vastus lateralis and
gastrocnemius skeletal muscle, inguinal and epididymal adipose tissue, heart and liver
were collected. All harvested tissues were snap frozen in liquid nitrogen immediately,
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and stored at -80°C until isolation of RNA and whole cell extracts and used for further
analysis.
2.9 Proteasome Activity Assay
The proteasome activity was assayed using three proteasome substrates as per the
manufacturer’s instructions (Millipore and Boston Biochemical). The assay kit
determines proteasome activity based on recognition of Ac-Leu-Leu-Val-Tyr-AMC
(LLVY) for chymotrypsin-like activity, Ac-Arg-Leu-Arg-AMC (RLR) for trypsin-like
activity and Ac-Nle-Pro-Nle-Asp-AMC (nLPnLD) for caspase-like activity and is based
on detection of the flurophore 7-amino-4-methylcoumarin (AMC) after cleavage from the
labeled substrate. Proteasome activity in C2C12 cells as well as in gastrocnemius skeletal
muscle was measured using a 20S Proteasome Activity Assay Kit according to the
manufacturer’s instructions. In brief, the cell and tissue lysates were harvested in 50 mM
Tris-Cl, pH 7.4 with 25 mM KCl, 2 mM MgCl2, 0.1% Triton X-100, 2 mM ATP, 2 mM
PMSF. Caspase-like, chymotrypsin-like and trypsin-like proteasome activity was
measured in triplicate by incubating 20 µg per sample of each lysate with a fluorophore
7-Amino-4-methylcoumarin (AMC) labeled peptide substrate nLPnLD-AMC, LLVYAMC and RLR-AMC and at 37 0C for 60 min and the free AMC released by proteasome
activity was quantified using a 380/460 nm filter set (Molecular Devices, Sunnyvale,
CA). Proteasome activity is reported as RFU/µg protein/hr. Each sample was measured in
triplicate both in the presence and in the absence of epoxomicin (20 µM), a highly
specific 26S proteasome inhibitor (BostonBiochem, Cambridge, MA) to account for any
non-proteasomal degradation of the substrate.
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2.10 Insulin ELISA Assay
Blood from randomized KK-Ay mice on LFD or PMI 5011 diet (n=8) was
collected at baseline, 4 weeks, and 8 weeks and processed as above to collect serum.
Insulin levels were determined using an insulin assay kit according to manufacturer’s
instructions (Downers Grove, IL, USA). Blood insulin levels were measured in duplicate
by incubating 2.5 µls of serum sample in an antibody-coated microplate for 2 hours at 4
ºC. Wells were washed and then incubated with anti-insulin enzyme conjugate for 30
minutes at room temperature. Wells were washed and then incubated with enzyme
substrate solution for 40 minutes in the dark. The enzyme reaction was stopped with 1 N
sulfuric acid and the A450 and A630 values were measured within 30 minutes of stopping
the reaction. Insulin concentrations were calculated using a standard curve based on A450
minus A630 values.
2.11 Glucose Assay
Blood from the KK-Ay mice on a low fat diet (LFD) or LFD supplemented with
PMI 5011 (n=8) was collected at baseline, 4 weeks, and 8 weeks. Glucose levels were
determined using a glucose assay kit according to manufacturer’s instructions (Ann
Arbor, MI, USA). In brief, blood was collected via tail snip, held on ice for 60 minutes
for blood to clot and then spun in a centrifuge for 20 minutes at 5,000 x g. Blood serum
was then separated. Blood glucose was measured in triplicate by incubating 5 µls of
serum sample with glucose enzyme mixture at 37ºC for 10 minutes. Absorbance at 500520 was read to determine glucose levels and calculated as mg/dl based on a standard
curve.
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2.12 H&E Staining of Skeletal Muscle

At the end of the study, both the control and PMI 5011 mice were further divided
into 2 groups (N=4) each. Insulin (1.5 U/kg intraperitoneal injection) was given to one
half of the mice (control, N=4; PMI 5011 N=4) and an equal volume of physiological
saline was administered to the remainder of the other half of mice (control, N=4; PMI
5011 N=4). The mice were euthanized ninety minutes post-injection and gastrocnemius
skeletal muscle tissue was harvested and placed in 10% formalin for paraffin embedding
and sectioning that was performed by the Pennington Biomedical Research Center
Imaging Core. Sections were stained with hematoxylin and eosin stain and slides were
scanned using Nanozoom software. Images were then reviewed with the Nanozoom
software and the area of cross-sectional segments were analyzed for myofiber size using
Image J software.

2.13 Statistical Analysis

GraphPad Prism 5 software was used for statistical analysis of all cell-based and
animal- based assays, each completed with a minimum of three replicates. A two-tailed
student’s t test was used to compare means ± SEM for all variables.

2.14 HOMA-IR Analysis
The HOMA-IR or homeostatic model assessment is a method commonly used to
quantify and assess insulin sensitivity (Matthews and Hosker 1995). It is a mathematical
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equation that relates fasting plasma glucose levels to fasting insulin levels. (fasting
Glucose (mmol/L) x fasting Insulin (mU/L) / 22.5). Homeostasis Model of Assessment Insulin Resistance (HOMA-IR) was calculated using the HOMA-IR Calculator version
0.3 based on the formula; fasting Glucose(mmol/L) x fasting Insulin(mU/L) / 22.5 for
each individual mouse. http://hcvsociety.org/files/HOMACalc.htm.
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CHAPTER 3: IN VITRO STUDIES
3.1 Results
A. Dexamethasone-Induced Model of Insulin Resistance In Vitro
Glucocorticoids such as dexamethasone decrease the rate of protein synthesis and
increase the rate of protein breakdown causing atrophy of skeletal muscle that is under
the regulation of insulin and insulin-like growth factor-I (IGF-I) (Goldberg, et al., 1980
and Lofberg et al., 2002). Muscle atrophy is upregulated in insulin resistant states such
as those induced by glucocorticoids. The glucocorticoid-induced protein degradation is
due to activation of the ubiquitin-proteasome system (Menconi, et al., 2008; Tiao, et al.,
1996; Schakman, et al., 2008) and administration of the synthetic glucocorticoid,
dexamethasone (DEX), results in increased expression of the two muscle specific E3
ubiquitin ligases Atrogin-1 and MuRF-1, (Menconi, et al., 2008; Sandri, et al., 2004; Stitt,
et al., 2004) whose activity leads to muscle atrophy. The Dex-induced increase in
Atrogin-1 and MuRF-1 expression is dependent upon ligand binding to the glucocorticoid
receptor (Zhao, et al., 2009) leading to the activation of the transcription factors
FoxO1and FoxO3a that in turn upregulate the expression of Atrogin-1 (Sandri, et al.,
2004; Skurk, et al., 2004) and MuRF-1 (Waddell, et al., 2004). Therefore, the effect of
PMI 5011 on components of insulin signaling and the DEX-induced expression of the
two E3 ubiquitin ligases, Atrogin-1 and MuRF-1 in vitro was examined by treating
C2C12 myotubes with the synthetic glucocorticoid dexamethasone at 1 µM for 24 hours.
As shown in Figure 3.1, treatment with dexamethasone significantly increased protein
expression of both E3 ubiquitin ligases, Atrogin-1 and MuRF-1 compared to controls
28

(p=0.0008 and p=0.0002 respectively), in agreement with previous studies (Menconi, et
al., 2008; Sandri, et al., 2004; Stitt, et al., 2004). These results also demonstrate a
significant reduction (p=0.001) in phosphorylation of Akt (serine 473) in the presence of
DEX, indicative of insulin resistant states. Sacheck et al. (2004), showed that coincubation of DEX with IGF-1 or insulin in vitro blocked DEX-induced myotube atrophy.
As demonstrated previously by Ribnicky, et al., 2006, Cefalu, et al., 2008, Wang, et al.,
2008 & 2010 and Obanda, et al., 2012, PMI 5011 improves carbohydrate metabolism by
enhancing the molecular events of insulin action in skeletal muscle. To test the
hypothesis that treatment of the myotubes with increasing concentrations (3 µg/ml-30
µg/ml) of the botanical extract PMI 5011 in the presence of dexamethasone would block
the DEX-induced expression of the E3 ubiquitin ligases Atrogin-1 and MuRF-1, C2C12
myotube cells were treated with 1 µM DEX for 24 hours in the presence or absence of
PMI 5011 and harvested for whole cell extracts that were subjected to immunoblotting
and probed for both Atrogin-1 and MuRF-1 protein expression in addition to
phosphorylation of (serine 473) Akt. We found that there was a significant decrease in
the DEX-induced expression of Atrogin-1 and MuRF-1 with all three-treatment
concentrations of PMI 5011 compared to DEX alone. Importantly, we found that
treatment of C2C12 myotubes with 1µM DEX inhibited the phosphorylation of Akt
(serine 473) compared to controls cells as seen previously (p=0.001). In the presence of
10 µg/ml PMI 5011 and 30 µg/ml PMI 5011 alone there was a significant increase in
phosphorylation of (serine 473) Akt (p=0.0001, p=0.05 respectively) compared to DEX
alone without insulin stimulation suggesting that PMI 5011 may act like insulin in that it
can activate the phosphorylation of Akt.
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Figure 3.1 Effects of PMI 5011 on
p-Akt, MuRF-1 and Atrogin-1
expression in dexamethasone
treated C2C12 myotubes. Whole
cell extracts were prepared from
differentiated C2C12 myotubes
treated with and without 1 µM Dex
for 24 hours with and without PMI
5011 overnight. 30 µg of the
protein extracts were separated by
SDS-PAGE, transferred to
nitrocellulose, and subjected to
Western blot analysis.

We quantified the effect of PMI5011 on the expression of Atrogin-1 and MuRF-1
proteins in the presence of dexamethasone and the effect is reported as a fold change
relative to the expression of each ligase under control conditions in Figure 3.2.

Figure 3.2 Densitometry of western blots on the effects of PMI 5011 on the
expression of phospho-Akt, MuRF-1 and Atrogin-1 in Dexamethasone treated
C2C12 myotubes. Densitometry was performed using the Un-Scan-It software program.
The fold change over control for phospho-Akt, MuRF-1 and Atrogin-1 protein levels
were analyzed from three independent experiments, as well as fold changes over DEX
with only comparisons for controls shown here for simplicity. The data were reported as
the mean -/+ standard deviation. *=P≤0.05. Statistics are un-paired, two-tailed student’s
t test.
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To determine the effect of PMI 5011 on atrogin-1 and MuRF-1 mRNA levels in
this system, myotubes were again treated with 1 µM dexamethasone for 24 hours and
treated with or without PMI 5011 overnight and then harvested for RNA isolation. RNA
was reverse transcribed and cDNA was used for Quantitative real-time PCR analysis. As
shown in Figure 3.3A, in the presence of 1 µM dexamethasone we observed a significant
increase (p=0.0002) in atrogin-1 mRNA expression (normalized to cyclophilin B)
compared to control cells. Treatment with the botanical extract PMI 5011 at 10 µg/ml
significantly (p=0.003) decreased this dexamethasone-induced increase in atrogin-1
mRNA levels. PMI 5011 had no effect on atrogin-1 mRNA levels alone. As shown in
Figure 3.3B, in the presence of PMI 5011 alone, we observed a significant decrease
(p=0.001) in MuRF-1 mRNA expression compared to control cells. When treated with 1
µM Dex, MuRF-1 expression was significantly upregulated (p=0.0002) as compared to
untreated control cells and again we observed that treatment with 10 µg/ml PMI 5011
significantly (p=0.0002) decreased the dexamethasone-induced increase in MuRF-1
mRNA expression levels. On both the protein and mRNA level, PMI 5011 is able to
regulate the DEX-induced expression of these two key mediators of skeletal muscle
atrophy as well as enhancing the phosphorylation of Akt the serine-threonine protein
kinase that is a key determinant of FoxO-mediated transcriptional regulation of both
atrogin-1 and MuRF-1.
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Figure 3.3 The mRNA expression of atrogin-1 and MuRF-1 in DEX and PMI 5011
treated myotubes. RNA extracts were prepared from C2C12 myotubes treated with and
without 1 µM Dex for 24 hours with and without PMI 5011 at 10 µg/ml overnight. 1 µg
of RNA was reverse transcribed and cDNA was analyzed with qRT-PCR for atrogin-1
and MuRF-1 mRNA expression normalized to cyclophillin B. The data are reported as
the mean -/+ standard deviation from three independent experiments. (A) *** = p<0.001
at 1 µM Dex compared to control; ** = p<0.01 at 1 µM Dex/PMI 5011 compared to 1
µM Dex. (B) PMI 5011 alone *** = p<0.001 compared to control; 1 µM Dex *** =
p<0.001 compared to control; 1 µM Dex /PMI 5011 *** = p<0.001 compared to 1 µM
Dex alone.
B. Free Fatty Acid-Induced Model of Insulin Resistance In vitro.
FFA-induced insulin resistance occurs predominately in skeletal muscle (Boden,
2006). A gradual increase in triglycerides, diacylglycerol (DAG) and the long chain
acyl-CoA within muscle cells caused by elevated FFAs is thought to be the underlying
cause of insulin resistance in skeletal muscle. This accumulation leads to inhibition of
PI3K activation of Akt, thereby inhibiting insulin signaling. Chavez et al., 2005, showed
that in C2C12 myotubes, free fatty acids (FFA) inhibited the insulin stimulation of
Akt/PKB signaling that regulates glucose uptake in addition to protein synthesis and the
transcriptional regulation of both Atrogin-1 and MuRF-1 atrogenes involved in skeletal
muscle atrophy. To determine the effect of PMI 5011in another model of insulin
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resistance in vitro, we treated C2C12 myotubes with palmitic acid. Previous studies
showed the saturated FFA palmitate inhibits insulin signaling in C2C12 myotubes as
measured by phosphorylation of Akt (Chavez, et al., 2005). Therefore, the C2C12
myotubes were treated with 200µM palmitic acid in the presence or absence of PMI 5011
overnight. The following day, the cells were serum deprived for 2 hours prior to insulin
stimulation with 100nM insulin for 4 hours before harvesting for whole cell extracts and
RNA. As shown in Figure 3.4 and quantified in Figure 3.5, treatment with 200µM
palmitic acid significantly increased both Atrogin-1 and MuRF-1 (p=0.0008 and
p=0.0005 respectively) protein expression as compared to control cells while blocking
insulin-stimulated phosphorylation (serine 473) of Akt (p=0.0006), confirming that
palmitate induced insulin resistance in the C2C12 myotubes in our experiments. In the
presence of PMI 5011, the palmitate-induced expression of both Atrogin-1 and MuRF-1
protein levels was significantly lowered (p=0.004 and p=0.05 respectively) compared to
palmitate alone-induced expression of these two atrogenes. In addition, , as seen in
dexamethasone-induced insulin resistance, Atrogin-1 and MuRF-1 protein expression
levels were significantly lowered in the presence of insulin combined with PMI5011 (10
µg/ml) than with insulin alone (p=0.001 and p=0.008 respectively). This again
demonstrates that PMI 5011 is able to enhance the effects of insulin in this FFA-induced
insulin resistant model. In conjunction with decreased levels of palmitate-induced
expression of both Atrogin-1 and MuRF-1, treatment with PMI 5011 in the presence of
insulin results in a significant increase in phosphorylation (serine 473) of Akt (p=0.0002).
This is the most exciting result in that insulin alone is unable induce phosphorylation of
Akt in palmitate-induced insulin resistance. Additionally, PMI 5011 enhances the action
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of insulin, restoring an insulin sensitive state as measured by Akt phosphorylation. The
effect of PMI5011 extended to control cells not treated with palmitate. We observed that
treatment with 10 µg/ml of PMI 5011 in the presence of insulin increased the levels of pAkt (p=0.0002) over that of insulin stimulation alone suggesting that PMI 5011 is able to
enhance the activity of insulin in myotubes in both insulin sensitive and, more important,
insulin resistant states.

Figure 3.4 The effects of PMI 5011 on phospho-Akt, MuRF-1 and Atrogin-1
expression in free fatty acid induced insulin resistant C2C12 myotubes. Whole cell
extracts were prepared from differentiated C2C12 myotubes treated with and without 200
µM palmitic with and without PMI 5011 overnight. Cells were serum deprived for 2
hours prior to stimulation with 100 nM insulin for 4 hours prior to harvest. 30 µg of
extracts were separated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis.
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Figure 3.5 Densitometry of the western blots demonstrating the effects of PMI 5011
on p-Akt, MuRF-1 and Atrogin-1 expression in free fatty acid induced insulin
resistant C2C12 myotubes. Densitometry was performed using Un-Scan-It software
program and statistics were performed using GraphPad Prism software. The fold change
over control for phospho-Akt, MuRF-1 and Atrogin-1 protein levels were analyzed from
three independent experiments, as well as for fold changes over PA alone. For simplicity
sake, only comparisons for fold change over control are shown here. The data were
reported as the mean -/+ standard deviation. *=P≤0.05, ***=p≤0.0001. Statistics are unpaired, two-tailed student’s t test.
Next, to examine the effects of PMI 5011 on mRNA expression levels of atrogin1 and MuRF-1, myotubes were again treated with 200µM palmitic acid overnight in the
presence or absence of PMI 5011. The following day, cells were serum deprived for 2
hours prior to insulin stimulation with 100nM insulin for 4 hours before harvesting for
RNA extracts. RNA was isolated, reverse transcribed and cDNA was used for
Quantitative real-time PCR analysis. As shown in Figure 3.6A, atrogin-1 mRNA
expression was significantly upregulated (p=0.02) in the presence of palmitate, compared
to control cells. In the presence of insulin alone, PMI 5011 alone, and in the presence of
both PMI 5011 and insulin FFA-induced atrogin-1 mRNA expression levels were
significantly downregulated (p=0.0002, p=0.0004, and p=0.0001 respectively) compared
to palmitate treatment alone. As shown in Figure 3.6B, MuRF-1 mRNA expression was
not affected by the presence of palmitic acid or PMI 5011 compared to controls.
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Figure 3.6 The mRNA Expression of atrogin-1 and MuRF-1 in Free Fatty AcidInduced Insulin Resistant Myotubes Treated with PMI 5011. RNA extracts were
prepared from C2C12 myotubes treated with and without 200 µM palmitate (PA) with
and without PMI 5011 overnight. Cells were serum deprived for 2 hours prior to
stimulation with 100 nM insulin (INS) for 4 hours prior to harvest. 1 µg of RNA was
reverse transcribed and cDNA was analyzed with qRT-PCR for atrogin-1 and MuRF-1
mRNA expression normalized to cyclophilin B. The data are reported as the mean -/+
standard deviation from three independent experiments. (A) * = p<0.02 at 200 µM PA
compared to control; ***= p<0.0002 at 200 µM PA/INS compared to 200 µM PA alone;
200 µM PA /PMI 5011 *** = p<0.0004 compared to PA alone; PA/5011/INS *** =
p<0.0001 compared to PA alone.

Next, to answer the question does PMI 5011 alter the effects of insulin on
proteasome activity and ubiquitylation in vitro these activities were examined. As shown
in Figure 3.7A, proteasomal activity is significantly decreased in C2C12 myotubes in the
presence of insulin, PMI 5011 and in the presence of both insulin and PMI 5011. This
demonstrates that PMI 5011 modulates proteasome activity alone or by enhancing
insulin’s effects on regulation of proteasomal activity. In all conditions, inhibition of
PI3K signaling is associated with increased proteasomal activity. This indicates that PMI
5011 enhances the effects of insulin on proteasomal activity that is PI3K-dependent. In
addition, we studied the effects of PMI 5011 on ubiquitylation levels in the myotubes.
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We found that the levels of steady-state ubiquitylation were substantially reduced in the
presence of both insulin and PMI 5011. However, in the presence of PMI 5011 alone or
insulin alone, the levels of ubiquitylation were unchanged as shown in Figure 3.7B. In
the presence of the PI3K inhibitor wortmannin, the effects of PMI 5011 on ubiquitylation
are blocked, indicating that the observed decrease in ubiquitylation in the presence of
PMI 5011 and insulin require the activation of PI3K.

Figure 3.7 PMI 5011 Enhances the Effect of Insulin on Proteasome Activity and
Inhibits Ubiquitylation in Myotubes. C2C12 myotubes were treated with 10 µg/ml of
PMI 5011 overnight. The cells were then incubated with wortmannin (200 nM) for 1
hour and then treated with insulin (100 nM) for 2 hours. (A) The cells were harvested
and assayed for the proteasomal chymotrypsin-like protease activity. MgATP was added
to the lysis buffer to maintain the 26S structure of the proteasome. The data is reported
as the mean -/+ standard deviation from three independent experiments. A=compared to
control; b=compared to related treatment (-) wortmannin; * = p<0.05, ** = p<0.01. (B)
Whole cell extracts were subjected to SDS-PAGE followed by western blot analysis
using an anti-ubiquitin antibody to assay the level of generalized ubiquitylation. The data
are representative of three independent experiments.
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3.2 Discussion
In light of the previous findings demonstrating that PMI 5011 enhances insulin
signaling and increases protein in skeletal muscle from KK-Ay mice, a murine model of
insulin resistance (Wang, et al., 2011), we hypothesized that the muscle atrophy
associated with type 2 diabetes could be attenuated with treatment of PMI 5011. We
predicted that PMI 5011 would do so by decreasing protein degradation, either through
regulation of the two-muscle specific E3 ubiquitin ligases Atrogin-1 and MuRF-1 or by
directly regulating proteasome activity. Because various models of skeletal muscle
atrophy show increases in E3 ubiquitin ligases atrogin-1 and MuRF-1 gene expression
(Lecker, et al., 2004) we chose to evaluate the effect of PMI 5011 on the expression of
these two ligases in two highly accepted models of insulin resistance associated with
muscle atrophy: glucocorticoid and FFA-induced models of insulin resistance. Our in
vitro studies using C2C12 myotubes show that PMI 5011 indeed has significant effects
on the expression of these two ligases in insulin resistance. Studies have shown that
administration of the synthetic glucocorticoid, dexamethasone (DEX), results in an
increased expression of the two E3 ubiquitin ligases; Atrogin-1 and MuRF-1 (Menconi,
et al., 2008; Sandri, et al., 2004; Stitt, et al., 2004) that leads to myotube atrophy. Indeed,
we found that treatment of myotubes with DEX increased levels of both ligases. On the
protein and mRNA level, PMI 5011 decreased the glucocorticoid-induced expression of
MuRF-1. The proteasome is unable to degrade large myofibrillar proteins that are the
primary group of targeted proteins in skeletal muscle associated with atrophy (Munoz, et
al., 1993). MuRF-1 dependent ubiquitylation of skeletal muscle proteins accounts for the
large majority of ubiquitin modifications associated with muscle atrophy and it has been
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shown to interact directly with and regulate the ubiquitylation of several myofibrillar
proteins (Cohen, et al., 2009; Clarke, et al., 2007). Our data is consistent with PMI 5011
regulation of MuRF-1 in our hormone-induced model of insulin resistance and muscle
atrophy. Our second model of insulin resistance mimics the elevated physiological level
of free fatty acids that causes muscle (peripheral), hepatic and vascular insulin resistance
(Boden, 1997). We found that treatment with palmitic acid significantly increased the
levels of both Atrogin-1 and MuRF-1 protein expression and completely blocked the
phosphorylation of Akt confirming our model of insulin resistance in C2C12 myotubes.
In the presence of PMI 5011 and insulin, phosphorylation of Akt was restored although
insulin alone and PMI 5011 alone were unable to induce phosphorylation of Akt in
palmitate-induced insulin resistant myotubes. This indicates that PMI 5011 is able to
restore insulin sensitivity to the cells. Unlike the DEX-induced model of insulin
resistance reported here, MuRF-1 gene expression was unaffected by PMI 5011 treatment
in palmitate-induced insulin resistant myotubes. In fact, there was little effect of palmitic
acid on induction of MuRF-1 gene expression in this model suggesting a lesser role of
MuRF-1 in FFA-induced insulin resistance. Perhaps this is due to the more subtle
skeletal muscle atrophy associated with insulin resistance of type 2 diabetes than what is
observed in glucocorticoid-induced muscle atrophy models since MuRF-1 is the main
ligase involved in degradation of larger myofibrillar proteins. Atrogin-1 gene expression
was however, significantly upregulated with palmitate and in the presence of both PMI
5011 and insulin this FFA-induced gene expression was attenuated. Atrogin-1 may play
a larger role in the sometimes more subtle atrophy associated with type 2 diabetes.
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Overall, PMI 5011 enhances phosphorylation of Akt the potent serine-threonine
kinase that is a dynamic regulator of insulin signaling, skeletal muscle hypertrophy and
transcriptional regulator of atrogene expression. The mechanisms by which phospho-Akt
targets Atrogin-1 or MuRF-1 in this system is yet to be determined.

We know that

phosphorylation of Akt leads to the inhibition of FoxO transcription factors that in turn
are excluded from the nucleus where they can no longer upregulate the expression of
Atrogin-1 and MuRF-1. However, the effects of PMI 5011 on the expression levels of
these transcription factors have not been evaluated to date in vitro. In addition, it is also
known that insulin also activates the mTOR pathway, leading to an increase in protein
synthesis that may regulate the rate of protein degradation through “cross-talk” with the
ubiquitin-proteasome system (Lagirand-Cantaloube, et al., 2008). This may extend to the
down regulation of Atrogin-1 and MuRF-1 that is observed with treatment of PMI 5011
in the presence of insulin. Another possible mechanism by which PMI 5011 regulates
protein degradation is via the translation initiation factor eIF3f that is a known substrate
and target of Atrogin-1 (Lagirand-Cantaloube, et al., 2008). PMI 5011 decreases both
protein and mRNA levels of Atrogin-1, and it is therefore possible that PMI 5011 also
increases protein content by indirectly blocking the degradation of eIF3f by
downregulating Atrogin-1 expression. We found that PMI 5011 enhanced insulin
signaling in a way that may help to maintain skeletal muscle mass via restoration of the
effect of insulin on protein degradation in skeletal muscle. These in vitro studies in
C2C12 myotubes suggest a potential role for PMI 5011 in regulating muscle specific
ubiquitin ligases involved with the ubiquitin proteasome and protein degradation in
skeletal muscle. PMI 5011 may have therapeutic implications for the treatment of
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muscle loss in a range of catabolic diseases including insulin resistance associated with
type 2 diabetes. The following chapter will discuss the effects of PMI 5011 in regulating
skeletal muscle atrophy in a murine model of insulin resistance in vivo.
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CHAPTER 4: IN VIVO STUDIES
4.1 Results
To examine the in vivo effects of PMI 5011 on the activity of the ubiquitin
proteasome system, a murine model of obesity-related insulin resistance and diabetes
known as KK.Cg-Ay/+ mice was used. The inbred mouse strain KK, established in Japan
as a diabetic strain, develops non-insulin-dependent diabetes mellitus with mild obesity,
mainly due to insensitivity of the peripheral tissue to insulin (Suto, et al., 1998).
Diabetes and obesity in the KK mouse alone is fairly moderate but introducing the Ay
allele (KK-Ay) worsens the pathophysiological condition of overt diabetes with
accompanying hyperinsulinemia. In the KK-Ay mouse strain, diet-induced obesity is
caused by a mutation of the yellow obese gene Ay that leads to insulin resistance of the
adipose tissue. This leads to glucose intolerance, insulin resistance and the development
of diabetes in the mice that is secondary to diet-induced obesity or aging (Ikeda, 1994).
The mechanism for obesity caused by the Ay allele is thought to be due to the agouti
peptide. Ectopic expression of the agouti peptide can act as an antagonist to the
melanocortin 4 receptor and inhibit the action of α-melanocyte-stimulating hormone
signals (Huszar, et al., 1997). It is not clear whether the diabetic and hyperglycemic
effects related to the Ay allele occur in a simple additive manner or whether impairments
result from complex interactions between diabetic genes already present in the genome
(Suto, et al., 1998). Obesity-related insulin resistance that precedes hyperglycemia,
hyperinsulinemia, glucose intolerance and dyslipidemia and the resulting metabolic
complications (Mittenforfer, 2011) occurs in numerous tissues including skeletal muscle
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tissue. The KK-Ay model therefore provides a model for observing the effects on PMI
5011 on skeletal muscle protein degradation associated with obesity-related insulin
resistance. This mouse model of insulin resistance and diabetes was used in earlier
studies that established PMI 5011 regulates glucose metabolism and insulin signaling in
skeletal muscle (Wang, et al., 2011). Therefore, we carried out our studies on the effect
of PMI 5011 on the ubiquitin-proteasome system in skeletal muscle using the KK-Ay
strain. Figure 4.1., shows the study design. At the end of the study at week 12 tissues
were harvested for gene expression analysis, protein analysis, proteasomal and nonproteasomal activity.

Figure 4.1 In vivo Study Design. Male KK-Ay mice (n=18) were singly housed and
randomly divided into a control group (N=9) and a PMI 5011-treated group (5011; n=9).
Body weight and food intake measurements were taken weekly. Baseline, week 4 and 8
were fasting glucose and blood serum collection for insulin ELISA. Study ended at week
12.
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As part of our data collection, body weight measurements were taken weekly on
each individual mouse. As shown in Figure 4.2., by week 8 those animals on PMI 5011
had a small, but significant increase in body weight compared to the control animals. In
previous studies by Wang et al., 2011 there was no effect on body weight in KK-Ay mice
on the PMI 5011 diet compared to control animals.

Figure 4.2 Body Weight Measurements. Body weights of individual mice were taken
weekly. Mice were measured in grams. PMI 5011 mice were slightly, but significantly
heavier than control mice on LFD (p≤0.05).
Food intake measurements were also measured weekly on individual mice. As
shown in Figure 4.3, the food intake for the PMI 5011supplemented animals was slightly
(p<0.05) higher than control mice. This may account for the slight increase in body
weight of the PMI 5011 mice.
Although there was a slightly higher body weight in the PMI 5011 fed mice, this
weight gain did not correlate with higher blood glucose (Figure 4.4) or insulin levels
(Figure 4.5) in these animals. Serum samples were analyzed for glucose levels with a
colorimetric hexokinase glucose assay according to manufacturer’s instructions. As
shown in Figure 4.4, by week eight the PMI 5011 supplemented animals had a
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significantly lower blood glucose level compared to the control mice, in agreement with
previous studies (Wang, et al., 2011).

Figure 4.3 Food Intake Measurements. Food intake of individual mice was measured
weekly. Weights were measured in grams. PMI 5011 mice ate significantly (p<0.05)
more food than control mice on the low fat diet (Control).

Figure 4.4 Fasting Blood Glucose Levels. At baseline, 4 weeks, and 8 weeks,
individual mice were fasted for a period of 4 hours. Blood serum samples were taken via
tail tip bleed for blood glucose analysis using a glucometer. PMI 5011 treated mice had
significantly lower (p≤0.05) fasting glucose levels as compared to control LFD mice by
week 8.
Blood insulin levels were assayed by insulin ELISA for relative insulin levels
according to manufacturer’s instructions. As shown in Figure 4.5, in accordance with
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previous studies (Wang, et al., 2011) , we found that those mice on the PMI 5011 diet
had significantly lower levels of insulin by week 8 as compared to control mice on a low
fat diet alone.

Figure 4.5 Fasting Serum Insulin Levels. At baseline, 4 weeks, and 8 weeks,
individual mice were fasted for a period of 4 hours. Blood serum samples were taken via
tail tip bleed for blood insulin analysis in an insulin ELISA assay. PMI 5011 treated
mice had significantly lower (p≤0.05) fasting insulin levels as compared to control LFD
mice by week 8.
To assess the effect of PMI 5011 on insulin sensitivity in this highly insulin
resistant model, blood serum samples were obtained after a four-hour fast via tail tip
bleeds. In Figure 4.6, and in accordance with previous studies by Wang et al., 2011, we
found that the PMI 5011 supplemented mice had significantly lower HOMA-IR levels by
week 8 as compared to control mice on LFD alone. This reconfirmed that a defined lowfat diet containing 1% (w/w) of PMI 5011 increased glucose disposal in a murine model
that is glucose intolerant, insulin resistant, and has overt diabetes as seen previously
(Wang et al., 2011).
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Figure 4.6 Fasting HOMA-IR Levels. At baseline, 4 weeks, and 8 weeks, individual
mice were fasted for a period of 4 hours. Blood serum samples were taken via tail tip
bleed for blood insulin analysis in an insulin ELISA assay, as well as, blood glucose by
glucose assay. HOMA-IR was calculated using a standard formula of Glucose X
Insulin/22.5 = Glucose in Molar units (mmol/L). PMI 5011 treated mice had significantly
lower (p≤0.05) fasting HOMA-IR levels as compared to control LFD mice by week 8.
Insulin resistance associated with type 2 diabetes has been linked to skeletal
muscle loss, a condition known as muscle atrophy (Park, et al., 2009). Sishi, et al., 2010
demonstrated that diet-induced obesity leads to skeletal muscle atrophy and previous
studies in the KK-Ay murine model of obesity and diabetes showed that a diet
supplemented with the botanical extract PMI 5011 leads to an increase in skeletal muscle
protein content (Wang, 2011). Additionally, Lecker et al., 2004, found that multiple
types of skeletal muscle atrophy involve a common program of gene expression changes.
In particular, they found that polyubiquitins, Ub fusion proteins, ubiquitin ligases
Atrogin-1 and MuRF-1, several subunits of the 20S proteasome in addition to cathepsin L
were commonly activated. Specifically, in STZ-induced diabetic rats they found that the
levels of UbA, UbB, UbC, the ubiquitin-conjugating enzyme E2 variant 1 (Ube2v1),
ubiquitin ligases Atrogin-1 and MuRF-1and proteasomal subunits PSMA5 and PSMB3
were all elevated.
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In insulin resistant states, there is impaired signaling of the PI3K/Akt signaling
pathway that leads to an increase in ubiquitin-proteasome-dependent protein degradation
(Wang, et al., 2006).

In the first committed step of this system, ubiquitin, an abundant 8

kDa protein highly conserved in all eukaryotes and responsible for the post-translational
modification to other proteins is covalently attached to its substrate by glycine on its Cterminal residue to the lysine side chain of target proteins that results in an isopeptide
bond (Kercher, et al., 2006). Through several lysine residues onto ubiquitin itself,
additional ubiquitins moieties are added in a polyubiquitin chain that is the classic target
signal for degradation in the 26S proteasome (Wing, et al., 2011). This conjugation of
ubiquitin to target proteins involves ATP-dependent sequence of reactions that are
catalyzed by three enzymes; first, the E1 ubiquitin activating enzyme, second, the E2
ubiquitin conjugating enzyme, and third, the E3 ubiquitin ligases that provides substrate
specificity to the reaction (Pickart, 2004). Hershko et al., 1982, first discovered this
complex system in rabbit reticulocyte extracts in 1982. To date, there are approximately
30 genes encoding E2 ubiquitin conjugating enzymes and nearly 900 genes encoding E3
ubiquitin ligases. There are four known ubiquitin genes. Two of these genes encode
polyubiquitin and two encode ubiquitin-ribosomal fusion proteins (Wing, et al., 2011).
Lecker, et al.( 2004), found that in STZ-induced diabetic rat that UbA, UbB, and UbC
were upregulated by at least two fold in this model of diabetes. Based on this
information, we selected ubiquitin B, ubiquitin C, and Ubiquitin A-52 ribosomal fusion
protein that showed a 2.7, 2.9, and 2.0 fold change increase respectively in gastrocnemius
skeletal muscle from rats with diabetes (Lecker, et al., 2004) to assay the effects of PMI
5011 supplementation. We found that mice supplemented with PMI 5011 had a slight,
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although significant decrease in UbA52 gene expression (*=p≤0.05) compared to control
mice but had no effect on Ubiquitin B or Ubiquitin C expression as shown in Figure
4.7(A-C).
A.

B.

C.

Figure 4.7 PMI 5011 Regulates UbA52 Gene Expression, but Not Ubiquitin B or C.
RNA was isolated from skeletal muscle from control and PMI 5011 supplemented mice.
1 µg of RNA was reverse transcribed and cDNA was analyzed with qRT-PCR for Gene
expression for UBA52 (A), UBB (B), and UBC (C) mRNA expression normalized to
cyclophilin B. Results are reported as the mean -/+ standard deviation (N=4/group).
Significance is reported relative to control or insulin treated mice, as indicated. *=p
≤0.05.
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Next, we chose to evaluate the effects of PMI 5011 on mRNA expression of
Ube2v1 the ubiquitin-conjugating enzyme E2 variant 1 that showed a 3.0 fold change
increase in gene expression in gastrocnemius skeletal muscle from rats with diabetes
(Lecker, et al., 2004). The Ubiquitin E2 Variant (UEV) proteins share sequence and
structure similarity to E2 enzymes, however they lack the activity of the E2 enzymes.
Sancho, et al., 1998 were unable to demonstrate recombinant Human UEV-1-mediated
inhibition of E2 enzyme-catalyzed ubiquitylation, and suggested that UEV proteins
function to regulate ubiquitylation of proteins by directly modulating the transfer of
ubiquitin to specific substrates through E2 enzymes. It is thought that interactions of E2
enzymes with UEV proteins provide a higher degree of combinatorial possibilities and
direct a given enzyme to specific substrates and modulate its activity (Sancho, et al.,
1998). As shown in Figure 4.8, PMI 5011 significantly decreased (*=p≤0.05) the mRNA
levels of Ube2v1 in the presence and absence of insulin stimulation compared to control
mice
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Figure 4.8 PMI 5011 Regulates Gene
Expression of Ube2v1, the ubiquitinconjugating enzyme E2 variant 1. RNA
was isolated from skeletal muscle from
control and PMI 5011 supplemented mice.
1 µg of RNA was reverse transcribed and
cDNA was analyzed with qRT-PCR for
Gene expression for Ube2v1 mRNA
expression normalized to cyclophillin B.
Results are reported as the mean -/+
standard deviation (N=4/group).
Significance is reported relative to control
or insulin treated mice, as indicated.
*=p ≤0.05.
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There are two major classes of E3 ubiquitin ligases. One class is the HECT
domain class that contains around 90 genes and is known for accepting ubiquitin from the
E2 enzymes and transferring the bound ubiquitin to the substrate protein. The other class
is the largest class containing nearly 800 genes with conserved RING finger motif that
functions by binding both the substrate and E2 enzyme to coordinate the transfer of
ubiquitin from the E2 to the targeted substrate. (Pickart, 2004) The RING-type ligases
can be further divided into two classes. One group of the RING-type ligases are single
subunit proteins and the second group is composed of multi-subunit complexes typified
by the family of Skp-Cullin-F-box protein (SCF) ligases that have distinct subunits for
substrate recognition and E2 binding functions (Wing, et al., 2011). The two musclespecific E3 ubiquitin ligases associated with atrophy are Atrogin-1/MAFbx and MuRF-1.
Atrogin-1/MAFbx is an F-box containing protein that is part of a SCF ligase complex
where the F-box containing subunit is the critical substrate recognition component of the
complex (Bodine, et al., 2001 and Gomes, et al., 2001). MuRF-1 is a monomeric ligase
with a tripartite RING finger-B box-coiled-coiled motif. Numerous studies have shown
that an increase in these two muscle-specific ligases is involved in catabolic conditions
associated with muscle atrophy. MuRF-1 has been shown to interact with eight
myofibrillar proteins and thick filament proteins (Witt, et al., 2005). In addition, MuRF1 knock-out mice have normal muscle structure and function while deletion of MuRF1/MuRF-2 is lethal. After muscle denervation, MuRF-1 -/- mice are significantly less
susceptible to muscle loss compared to MuRF-1 wild-type mice (Bodine, et al., 2001).
Atrogin-1/MAFbx-1 has also been found to decrease transcription and translation of
muscle myofibrillar proteins and it was originally cloned because its mRNA was found to
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be the most highly induced in skeletal muscle in catabolic states such as fasting (Gomes,
et al., 2001). More important, mice lacking the atrogin-1 gene also show reduced rates
of muscle atrophy (Bodine, et al., 2001). Lecker et al., 2004, found that in studies of rats
with diabetes, there is a 9.1 fold increase in atrogin-1 mRNA expression levels. Due to
these important findings, we studied the effects of PMI 5011 on gene and protein
expression in the KK-Ay model of diabetes and insulin resistance. As shown in Figure
4.9A, those KK-Ay mice on the PMI 5011 diet had significantly lower levels (p ≤ 0.05) of
atrogin-1 expression compared to control mice in the gastrocnemius skeletal muscle. In
those animals that received insulin prior to the end of study, PMI 5011 animals also had
lower levels of atrogin-1 mRNA levels compared to control insulin-stimulated mice,
although the reduction was not significant. We next assessed the mRNA levels of MuRF1 in the KK-Ay mice on the PMI 5011 diet. We found that the PMI 5011 diet
significantly reduced (p≤0.05) levels of MuRF-1 gene expression compared to control
animals as shown in Figure 4.9B. In those animals that were insulin-stimulated prior to
tissue harvest, there was no observed effect of PMI 5011 on MuRF-1 gene expression.
Next, to assess the effects of diets enriched with PMI 5011 on the protein expression of
Atrogin-1 and MuRF-1 in skeletal muscle, we conducted immunoblotting analyses of
skeletal muscle collected from control mice and PMI 5011 supplemented animals, in the
absence or presence of insulin treatment. In addition to analysis of Atrogin-1 and MuRF1, we also assayed the effects of PMI 5011 on insulin signaling by studying the effects on
phosphorylation of Akt in the same mice.

52

Atrogin-1
relative mRNA levels

3

1.8

*

1.6
1.4
1.2
1.0
0.8

Control

MuRF-1
relative mRNA levels

1.0

0.7
0.6

Control

Insulin

Insulin/5011

1.1

0.8

0.5

1

0

5011

*

0.9

2

MuRF-1
relative mRNA levels

Atrogin-1
relative mRNA levels

2.0

1.0
0.9
0.8
0.7
0.6
0.5

5011

Insulin

Insulin/5011

Figure 4.9 PMI 5011 Regulates Atrogin-1 and MuRF-1 Gene Expression in Skeletal
Muscle. RNA was isolated from skeletal muscle from control and PMI 5011
supplemented mice. 1 µg of RNA was reverse transcribed and cDNA was analyzed with
qRT-PCR for atrogin-1 (A) and MuRF-1 (B) mRNA expression normalized to
cyclophilin B. Results are reported as the mean -/+ standard deviation (N=4/group).
Significance is reported relative to control or insulin treated mice, as indicated. *=p
≤0.05.
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As shown in Figure 4.10A and 4.10B, PMI 5011 significantly decreased both
Atrogin-1(p≤0.05) and MuRF-1(p≤0.05) protein expression in skeletal muscle. In
addition, PMI 5011 treatment improved insulin signaling in skeletal muscle as shown by
increased phosphorylation of Akt. Importantly, this increase in Akt phosphorylation is
associated with decreased expression of both Atrogin-1 and MuRF-1 protein expression.
Lastly, activation of Akt correlates with increased phosphorylation of FoxO3a (Figure
4.10A). Akt directly phosphorylates FoxO proteins, leading to inhibition of FoxO
transcriptional activity and blocking FoxO-dependent upregulation of both Atrogin-1 and
MuRF-1 ubiquitin ligases (Glass, 2005). FoxO1 and FoxO3a are both members of the
FoxO class of forkhead transcription factors and are downstream targets of Akt in
skeletal muscle. FoxO transcription factors are excluded from the nucleus when they are
phosphorylated by Akt. Therefore, phosphorylation of the FoxO proteins leads to
decreased gene expression of atrogin-1 and MuRF-1 (Sandri, et al., 2004). We sought to
determine if the downregulation of both Atrogin-1 and MuRF-1 in addition to
upregulation of phospho-Akt protein expression was related to the regulation of FoxO
phosphorylation. In order to do this, we measured the levels of total FoxO3a protein in
addition to the phosphorylated (serine 253) form of FoxO3a in the control and PMI5011
supplemented, with and without insulin stimulation. We found that PMI 5011
supplementation did correspond with increased phosphorylation of FoxO3a, as shown in
Figure 4.10A and 4.10B. When FoxO3a is phosphorylated downstream of p-Akt, it is
excluded from the nucleus where it can no longer upregulate the expression of Atrogin-1
or MuRF-1.
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A

B

Figure 4.10. PMI 5011 Regulates Atrogin-1, MuRF-1, p-Akt and p-FoxO3a protein
expression in skeletal muscle. (A,B) Whole cell extracts were processed from
gastrocnemius skeletal muscle from KK-Ay supplemented with and without the botanical
extract PMI 5011. Whole cells extracts were analyzed using SDS-PAGE followed by
western blot analysis for phosphor-Akt, total Akt, MuRF-1, Atrogin-1, p-FoxO3a, total
FoxO3a and β-actin loading controls. Fold change for phopsho-Akt/total Akt, phosphorFoxO3a/total FoxO3a, MuRF-1/total protein and Atrogin-1/total protein is reported in
(A) the PMI 5011 mice relative to control mice and (B) PMI 5011 mice relative to control
mice receiving insulin prior to tissue harvest. *=p≤0.05 and ***= p≤0.001.
Densitometry was performed using the Un-Scan-It software program.
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Although we do not provide direct evidence that FoxO3a is excluded from the
nucleus in this study, our data is consistent with decreased FoxO3a activity due to
phosphorylation, a possibility that is supported by the decrease we observe in gene
expression of atrogin-1 and MuRF-1. Future studies to determine cellular localization
with both immunoblotting of cytosolic and nuclear fractioned samples in addition to
immunolocalization would provide further evidence of PMI5011 regulation of atrogin-1
and MuRF-1 expression by AKT-mediated inhibition of FoxO3a activity.
Increased levels of ubiquitylated proteins in atrophying skeletal muscle occurs in
many catabolic states, including diabetes (Wing, 2004). The ubiquitin-modified proteins
are targeted for degradation at the proteasome and Atrogin-1 and MuRF-1 are the
primary ubiquitin ligases responsible for tagging the proteins for degradation. The
decrease in Atrogin-1 and MuRF-1 expression would be consistent with reduced levels of
ubiquitin modified proteins in the PMI5011 supplemented animals. Therefore, we
assessed the general levels of ubiquitylation in control and PMI 5011 supplemented mice.
As shown in Figure 4.11, the general ubiquitylation of skeletal muscle proteins are lower
in animals supplemented with PMI 5011 (N=4) compared to control animals (N=4). In
addition, the effect of insulin stimulation on ubiquitylation is enhanced by
supplementation of PMI 5011 (N=4) compared to insulin alone (N=4) (Figure 4.11B).
We next assayed the effect of PMI 5011 on the mRNA levels of two specific 20S
proteasomal subunits, the proteasome 20S subunit alpha 5 (PSMA5) and 20S subunit beta
3 (PSMB3) that are strongly upregulated with muscle loss (Lecker, et al., 2004) in a
study that used microarray analysis to examine the transcriptional adaptations of mRNA
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in normal muscle versus atrophying muscle in fasted mice or rats with renal failure,
cancer or diabetes (Lecker, et al., 2004).
A.

B.

Figure 4.11 PMI 5011 Reduces Steady-State Ubiquitylation Levels in Skeletal
Muscle. Whole cell extracts were isolated from skeletal muscle from control and PMI
5011 supplemented mice. The steady states of ubiquitylation were measured in (A)
control versus PMI 5011 supplemented mice and in (B) insulin-stimulated control versus
PMI 5011 supplemented mice. Extracts were subjected to SDS-PAGE followed by
western blot analysis using anti-ubiquitin and β-actin was used as a loading control.
Based on this study, we assayed the gene expression of proteasomal subunits
PSMA5 and PSMB3. PSMA5and PSMB3 showed a fold change of 2.25 and 2.27,
respectively in gene expression in gastrocnemius skeletal muscle in diabetic rats
compared to control rats (Price, et al., 1996; Mitch, et al., 1999). We found that KK-Ay
mice supplemented with PMI 5011 lead to small, but highly significant decrease (***=p
≤0.001)	
 in PSMA5 gene expression as shown in Figure 4.12A, but had no effect on
PSMB3 gene expression (Fig. 4.12B) in gastrocnemius skeletal muscle.
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Figrue 4.12 PMI 5011 Regulates Gene Expression of PSMA5, but Not PSMB3. Gene
expression for two proteasome subunits, PSMA5 (A) and PSMB3 (B) was analyzed by
real-time Rt-PCR. The data are reported as the mean -/+ standard deviation (N=4/group).
Statistical significance was compared to control mice. *=p≤0.05,***=p≤0.001.
At the epicenter of the ubiquitin-proteasome system is the 26S proteasome that
carries out the degradation of proteins. The 26S proteasome is a 2.5-MDa complex that
is composed of around 31 different subunits that are responsible for catalyzing protein
degradation. The 26S proteasome is composed of a barrel-shaped proteolytic core
complex called the 20S proteasome and is capped at one or both ends by a 19S regulatory
complex that recognizes ubquitinated proteins and then unfolds and translocate the
ubquitinated targets into the interior of the 20S complex where they are degraded into
smaller oligopeptides (Voges, et al., 1999). In the 20S portion of the proteasome, there
are six active sites; two sites are chymotrypsin-like, two are trypsin-like and two are
caspase-like in their activity (Kisselev, , 2006). The three pairs of proteolytic sites have
distinct substrate specificities. To be specific, the β5 proteolytic sites are chymotrypsinlike, the β2 sites are trypsin-like, and the β1 sites cleave after acidic residues and are
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referred to as post-acidic, post-glutamate peptide hydrolase or caspase-like (Britton, et al.,
2009). Chymotrypsin-like proteasome activity is required for proteasome-dependent
protein degradation in coordination with either one or both of the trypsin-like or caspaselike protease activity (Kisselev, et al., 2006).
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Figure 4.13. PMI 5011 Regulates Proteasomal Activity in Skeletal Muscle.
Proteasomal activity for caspase-like (A), chymotrypsin-like (B) and trypsin-like (C) was
assayed from whole cell extracts in a buffer containing MgATP to maintain the 26S
proteasome structure. The data are reported as the mean -/+ standard deviation
(N=4/group). Statistical significance was compared to control mice. *=p≤0.05,	
 
**=p≤0.01, ***=p≤0.001.

We next assessed the overall effects of PMI 5011 on each of the three
independent proteasomal activities in skeletal muscle.
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As shown in Figure 4.13, PMI

5011 substantially reduces chymotrypsin-like (A) and caspase-like (B) activity but had
only slight, however significant effects on trypsin-like (C) in gastrocnemius skeletal
muscle. In addition, we found that insulin-stimulation reduced all three types of activity
as shown in Figure 4.13 A, B, C.
In addition to ubiquitin proteasome protein degradation, there are several nonproteasomal proteolytic pathways. In fact, the ubiquitin proteasome is incapable of
breaking down complex proteins contained in myofibrils that actually constitute the bulk
of proteins found in skeletal muscle (Du, et al., 2004; Tiao, et al., 2004; Mitch, et al.,
1996). Therefore, additional proteases are required to release basic proteins that make up
myofibrils before the ubiquitin proteasome is able to recognize and degrade these
complex proteins that make up skeletal muscle (Du, et al., 2004). In order to accomplish
this, the calcium-dependent proteases known as calpains are most likely required (Wing,
et al., 2011). It is thought that calpain activity is important in releasing components of
myofibrils for degradation in the ubiquitin proteasome. In addition to the calpains,
another group of proteases capable of releasing more complex myofibers are the caspases.
Proapoptotic gene expression leads to activation of the caspases, which increases muscle
protein degradation and muscle atrophy (Vazeille, et al., 2008). Many studies have
shown that the proapoptotic protease caspase-3 is required to cleave the actinomyosin and
myofibril complexes of skeletal muscle proteins thereby generating actin fragments that
can then be degraded by the ubiquitin proteasome system (Plant, et al., 2009; Wang, et al.,
2010; Lee, et al., 2004). However, even in the absence of apoptosis, caspase-3 is
activated in rodent models of catabolic disease such as diabetes leading to cleavage of
skeletal muscle actin and this caspase-3 activation has been shown to be an initial critical
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steps in skeletal muscle loss (Lee, et al., 2004; Du, et al., 2004) much like that observed
in calpain coordinated protein degradation with the ubiquitin proteasome. One last
proteolytic system that also coordinately participates with ubiquitin proteasome protein
degradation is the lysosomal pathway. Although our studies did not address the effect of
PMI5011 on this group of proteases, the lysosomal proteases also play an important role
in skeletal muscle loss associated with disease. Cathepsins are the major lysosomal
proteases and it has been recognized that cathepsin L is a general marker of muscle
atrophy associated with disease (Bechet, et al., 2005). Cathepsin L is induced early in
catabolic states and has been found to be upregulated in type 2 diabetes (Huang, et al.,
2003). In addition, glucocorticoid-induced muscle wasting (Dardevet, et al., 1995) was
associated with increased levels of cathepsin B and D mRNA. These cathepsin proteases
of the lysosome likely act in concert with the ubiquitin proteasome (Baracos, et al., 1995;
Wing and Goldberg , 1995) in addition to caspases and calpains (Combaret et al., 1996)
or with both (Mansoor et al., 1996; Taillandier, et al., 1996) in coordinated degradation
of skeletal muscle proteins.
In order to study the effects of PMI 5011 on non-proteasomal activity in
gastrocnemius skeletal muscle we measured caspase-like, chymotrypsin-like and trypsinlike activity. We found that in addition to PMI 5011’s ability to regulate all three
activities of the proteasome, it also regulated non-proteasomal activity in skeletal muscle.
PMI 5011 significantly regulated chymotrypsin-like, caspase-like and trypsin-like nonproteasomal activity in skeletal muscle from the insulin resistant KK-Ay mice.
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Figure 4.14 PMI 5011 Regulates Non-Proteasomal Protease Activity in Skeletal
Muscle. Non-proteasomal activity for chymotrypsin-like (A), caspase-like (B) and
trypsin-like (C) was assayed from whole cell extracts in a buffer containing MgATP to
maintain the 26S proteasome structure. The data are reported as the mean -/+ standard
deviation (N=4/group). Statistical significance was compared to control mice.
*=p≤0.05,	
 **=p≤0.01, ***=p≤0.001.
As shown in Figure 4.14A, PMI 5011 alone significantly decreased nonproteasomal chymotrypsin-like activity (p≤0.05) in addition to insulin-administered
animals (p≤0.05). The most dramatic effect of PMI 5011 was observed in Figure 4.14B
where PMI 5011 alone significantly lowered non-proteasomal caspase-like activity
(p≤0.0001) in addition to insulin-stimulated mice (p≤0.0001) as compared to control
mice. Last, we found that PMI 5011 alone significantly decreased the non-proteasomal
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trypsin-like activity (p≤0.01) as seen in Figure 4.14C, as well as in insulin-stimulated
mice (p≤0.01) when compared to control mice. This data demonstrates that in addition to
regulating all three activities of proteasomal protein degradation, PMI 5011 has
significant effects on the regulation of three types of non-proteasomal activity as well.
Lastly, we performed histological H & E staining on gastrocnemius skeletal
muscle to access the differences in cross-sectional areas of myofibers between control
mice versus those mice supplemented with PMI 5011. In Figure 4.15A,B, we found that
those animals supplemented with PMI 5011 had significantly larger (p=0.02) myofibers
than control animals. Interestingly, we also found that those animals supplemented with
PMI 5011 had less fat deposition as shown by the degree of white striations in control
animal skeletal muscle compared to PMI 5011 supplemented mice in Figure 4.15A.
4.2. Discussion
The ethanolic extract of Russian tarragon (Artemisia dracunculus, L.) termed PMI
5011 was found previously to lower both serum glucose and insulin levels in KK-Ay
mice, a murine model of diabetes and insulin resistance as shown by Wang, , 2011. This
study also supported these findings that a diet supplemented with PMI 5011 improves
glucose disposal and enhances insulin sensitivity in a mouse model of insulin resistance
and diabetes. PMI 5011 has also been shown to enhance insulin signaling in skeletal
muscle through increased phosphorylation of Akt by Wang, et al., 2011. Because
PI3K/Akt signaling regulates components of the ubiquitin proteasome system associated
with muscle atrophy, we chose to evaluate the effects of PMI 5011on several components
of the ubiquitin proteasome system.
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Figure 4.15 Myofiber Size is Larger in the PMI 5011 Supplemented Diet. Crosssection and Longitudinal sections of gastrocnemius skeletal muscle from control and PMI
5011 supplemented mice. (A) Myofibers were stained with hematoxylin and eosin stain.
(B) Area of myofiber sizes from control and PMI 5011 supplemented mice. The data are
reported as the mean -/+ standard deviation (N=4/group). Statistical significance was
compared to control mice. *=p<0.05.
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Overall, we find that PMI 5011 regulates muscle mass in the presence of insulin
resistance by regulating the ubiquitin proteasome system on several levels. First, we
demonstrated that PMI 5011 regulates both protein and gene expression of the two
muscle-specific E3 ubiquitin ligases Atrogin-1 and MuRF-1 in vivo in gastrocnemius
skeletal muscle of KK-Ay mice. In our most striking evidence, we demonstrate that PMI
5011 significantly regulates all three activities of both proteasomal and non-proteasomal
protein degradation. We found that PMI 5011 significantly reduced both the
chymotrypsin and caspase-like protease activities in both the presence as well as absence
of insulin stimulation. The effects of PMI 5011 on trypsin-like proteasomal activity
were only significant in the presence of insulin. However, the non-proteasomal trypsinlike activity was significantly regulated in skeletal muscle of PMI 5011 supplemented
mice in both the presence and absence of insulin. Inhibition of the non-proteasomal
chymotrypsin-like activity by PMI 5011 is consistent with PMI 5011 inhibition of calpain
activity since the substrate used to measure chymotrypsin-like activity (Leu-Leu-ValTyr) is also used to assay calpain activity. PMI 5011 inhibition of calpain activity could
be particularly important for degradation of the myofibrillar proteins, the main target for
skeletal muscle protein degradation in muscle atrophy. MuRF-1 is the ubiquitin ligase
responsible for recognizing the myofibrillar proteins once they are cleaved by the
calpains (Guttman and Johnson, 1998). Therefore, our data is consistent with PMI 5011
regulation of the degradation of myofibrillar proteins at the step of calpain and ubiquitin
proteasome system recognition by MuRF-1 and the proteasome itself.
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We also show that the effect of PMI 5011 on the ubiquitin proteasome system is
mediated through PI3K/Akt signaling pathway as evidenced by an increase in
phosphorylated Akt in skeletal muscle. Activation of Akt directly inhibits FOXO
transcription factors thereby, blocking upregulation of both Atrogin-1 and MuRF-1
ubiquitin ligases (Glass, 2005). Our in vivo studies show that the increased
phosphorylation of Akt correlates with increased phosphorylation of FoxO3a, a
modification that renders FoxO3a inactive as a transcription factor. As a transcription
factor, FoxO3a regulates the gene expression of Atrogin-1 and MuRF-1. In addition,
FoxO-dependent transcription of Atrogin-1 and MuRF-1 is required for muscle loss
(Schakman, et al., 2008; Zhao, et al., 2007; Sandri, et al., 2004). Therefore, our findings
are consistent with the PMI 5011 regulation of Atrogin-1 and MuRF-1 expression via Akt
inactivation of Foxo3a. downregulation of both atrogin-1 and MuRF-1 gene expression
provides a possible link between PMI 5011 and the observed reductions of both Atrogin1 and MuRF-1 protein expression and Akt-dependent regulation of transcriptional
activity of FoxO3a. We also found that PMI 5011 regulated the gene expression of the
proteasomal subunit alpha 5 (PSMA5), as well as Ube2v1 the ubiquitin-conjugating
enzyme E2 variant 1 in skeletal muscle. In addition to controlling both proteasomal and
non-proteasomal activities in skeletal muscle in vivo, we found that the steady-state levels
of ubiquitylated proteins in skeletal muscle were also reduced in the PMI 5011
supplemented mice and this effect was enhanced in the presence of insulin. Lastly, we
found that PMI 5011 decreased the level of Ubiquitin A52 mRNA expression levels in
skeletal muscle.

This data provides evidence that suggests an overall and extensive

regulation of protein degradation in skeletal muscle by the botanical extract of the
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perennial herb Artemisia dracunculus L. (PMI 5011) in catabolic conditions such as
insulin resistance and type 2 diabetes. This broad regulation of activities involved in
protein degradation in skeletal muscle in vivo by PMI 5011 has important implications
for its therapeutic possibilities in atrophy associated with catabolic diseases.
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CHAPTER 5: SUMMARY AND CONCLUSIONS
5.1 Summary
The botanical extract, PMI 5011 lowers blood glucose and insulin levels and
enhances insulin signaling in skeletal muscle leading to preserved muscle mass through
regulation of protein degradation. Given the important role of skeletal muscle in glucose
disposal and protein storage in the body, the effect of PMI5011 on skeletal muscle
protein degradation may have implications for the treatment of type 2 diabetes.
Overall, we find that PMI 5011 regulates muscle mass in the presence of insulin
resistance by regulating the ubiquitin proteasome system on several levels. In the overall
process, ubiquitylation is carried out by a set of three enzymes, E1, E2 and E3. Ubiquitin
is first activated by ubiquitin-activating enzyme E1, in an ATP-dependent manner. Next,
the ubiquitin molecule is passed on to the second enzyme of the complex, E2 ubiquitinconjugating enzyme. Next, it is recognized by the final enzyme, E3, the ubiquitin protein
ligase that binds the target substrate and labels it with ubiquitin. The process can be
repeated until a short chain is formed, with three or more ubiquitin molecules targeting
the protein to the proteasome (Wing, 2005). We have demonstrated through our
experiments that PMI 5011 regulates almost every step of this process. As depicted in
the Figure 5.1, below, we show that PMI 5011 a) regulates the level of ubiquitin A52, a
form of ubiquitin that is fused with ribosomal protein L40 and may aid in assembling the
ribosome (Baker and Board, 1991) , b) regulates the activity of Ube2v1, a protein that
shares sequence and structure similarity to E2 enzymes and is thought to interact with E2
enzymes to provide a higher degree of enzyme specificity (Sancho, et al., 1998), c)
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regulates the two muscle-specific E3 ubiquitin ligases, Atrogin-1 and MuRF-1, d)
regulates steady-state levels of ubiquitylation, e) regulates the proteasomal subunit
PSMA5 gene expression and f) regulates all three activities of the proteasome.

a

PMI 5011

b
e

PMI 5011

f

d

c

Figure 5.1. PMI 5011 Regulates Several Levels of Ubiquitin Proteasomal Protein
Degradation.
In addition to overall regulation of the many facets of the ubiquitin proteasome
system, we provide further evidence regarding the mechanism by which PMI 5011
regulates the expression of Atrogin-1 and MuRF-1. We found in vitro and in vivo that
PMI 5011 enhanced phosphorylation of Akt. Our in vivo studies show that the increased
phosphorylation of Akt correlates with increased phosphorylation of FoxO3a, a
modification that renders FoxO3a inactive as a transcription factor. As a transcription
factor, FoxO3a regulates the gene expression of Atrogin-1 and MuRF-1 and FoxO-
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dependent transcription of Atrogin-1 and MuRF-1 is required for muscle loss (Schakman,
et al., 2008; Zhao, et al., 2007; Sandri, et al., 2004). Therefore, our findings are
consistent with the PMI 5011 regulation of Atrogin-1 and MuRF-1 expression via Akt
inactivation of Foxo3a. Additionally, PMI 5011 regulated the steady-state levels of
ubiquitylated proteins. Bachmair, et al., 1989 hypothesized that ubiquitylation of a
protein requires two steps: recognition of the targeted protein by a ubiquitin ligase
followed by attachment of ubiquitin to the protein. The PMI5011-mediated decrease in
ubiquitylation levels may be a consequence of the reduced expression of the two musclespecific ubiquitin ligases Atrogin-1 and MuRF-1 and a corresponding reduction in the
activity of each ligase. However, we cannot rule out the possibility that PMI5011 is
affecting recognition of a ubiquitin-modified protein at the proteasome.
Perhaps our most striking evidence that PMI 5011 inhibits skeletal muscle loss is
by inhibiting the actions of all three protease activities of the proteasome in vivo. This
project showed that the beneficial effect of PMI 5011 on insulin signaling extends to the
regulation of ubiquitin-proteasome activity in addition to non-proteasomal activity in
skeletal muscle, indicating that PMI 5011 is a potent inhibitor of overall skeletal muscle
protein turnover in vivo. All three activities of the proteasome including caspase-like,
chymotrypsin-like, and trypsin-like activities in skeletal muscle were significantly
reduced by PMI 5011 while the related activities of non-proteasomal proteases in skeletal
muscle were also significantly reduced by PMI5011. Lastly, we observed in histological
sections of Hematoxylin and Eosin (H & E) stained gastrocnemius muscle tissue that
PMI 5011 treated animals had larger overall myofiber size compared to KK-Ay controls,
providing morphological evidence of the beneficial effects of PMI 5011 in preserving
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muscle mass in the presence of insulin resistance. This extensive inhibition and
regulation of protein degradation in skeletal muscle is a very powerful means by which
PMI 5011 could potentially protect skeletal muscle mass in catabolic diseases such as
type 2 diabetes. In summary, these studies demonstrate that PMI 5011 regulates protein
degradation in insulin resistant states in vitro and in vivo. PMI 5011 may therefore be a
therapeutic target for the conservation of muscle mass in catabolic conditions such as
type 2 diabetes by directly targeting several components of the ubiquitin proteasome
system.
5.2 Conclusions
In conclusion, there is a dynamic balance between protein synthesis and
degradation that regulates muscle mass. Insulin resistance in type 2 diabetes is associated
with impaired glucose and protein metabolism of the skeletal muscle. The impaired
insulin signaling in skeletal muscle affects muscle mass by tipping the balance from
skeletal muscle protein synthesis and degradation toward degradation in a process that is
primarily regulated by the ubiquitin-proteasome system. As the major site of protein
breakdown the ubiquitin proteasome has been shown to be significantly upregulated in
muscle atrophy associated with insulin resistance (Park, et al., 2009; Wang, et al., 2006).
Studies have shown that an extensively characterized ethanol extract of Artemisia
dracunculus L (Russian Tarragon), termed PMI 5011, enhances insulin signaling in
human primary skeletal muscle cells and in a rodent model of insulin resistance (Wang,
et al., 2008 and Wang, et al., 2011) and this enhanced insulin signaling was associated
with an increase in protein levels in skeletal muscle (Wang, et al., 2011).
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This data provides evidence that suggests an overall and extensive regulation of
protein degradation in skeletal muscle by the botanical extract of the perennial herb
Artemisia dracunculus L. (PMI 5011) in catabolic conditions such as insulin resistance
and type 2 diabetes. One of the most important findings of this study was that PMI 5011
significantly regulated all three protease activities of the proteasome in addition to the
activity of three related non-proteasomal classes of proteases. Chymotrypsin-like
proteasome activity is required for overall ubiquitin-proteasome protein degradation in
coordination with either one or both of the trypsin-like or caspase-like proteasome
activities (Kisselev, et al., 2006). In fact, the proteasome is incapable of breaking down
complex proteins contained in myofibrils that actually constitute the bulk of proteins
found in skeletal muscle (Du, et al., 2004; Tiao, et al., 2004; Mitch, et al., 1996).
Therefore, additional proteases are required to release basic proteins that make up
myofibrils before the proteasome is able to recognize and degrade these complex proteins
that make up skeletal muscle (Du, et al., 2004). In order to accomplish this, the calciumdependent proteases known as calpains are most likely required (Wing, et al., 2011).

Of

the 14 genes encoding calpain proteases, 7 different calpains are expressed in skeletal
muscle and evidence has been provided that links calpain activation with increased
ubiquitin proteasome activity. It is thought that calpain activity is important in releasing
components of myofibrils for degradation in the ubiquitin proteasome. CAPN3 knockout mice show an abnormal accumulation of high molecular weight ubiquitin-protein
conjugates in muscle during reloading after disuse and this data that suggests an
important role for CAPN3 in ubiquitin-proteasome system degradation of products of
CAPN3 cleavage (Kramerova, et al., 2005). Inhibition of the non-proteasome
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chymotrypsin-like activity by PMI5011 is consistent with PMI5011 inhibition of calpain
activity since the substrate used to measure chymotrypsin-like activity (Leu-Leu-ValTyr) is also used to assay calpain activity (Guttman and Johnson, 1998). PMI5011
inhibition of calpain activity could be particularly important for degradation of the
myofibrillar proteins, the main target for skeletal muscle protein degradation in muscle
atrophy. MuRF-1 is the ubiquitin ligase responsible for recognizing the myofibrillar
proteins once they are cleaved by the calpains (Cohen, et al., 2009). Therefore, our data
is consistent with PMI5011 regulation of the degradation of myofibrillar proteins at the
step of calpain and ubiquitin proteasome system recognition by MuRF-1 and the
proteasome itself.
In addition to the calpains, another group of proteases capable of releasing more
complex myofibers are the caspases. Many studies have shown that the proapoptotic
protease caspase-3 is required to cleave the actinomyosin and myofibril complexes of
skeletal muscle proteins thereby generating actin fragments that can then be degraded by
the ubiquitin proteasome system (Plant, et al., 2009; Wang, et al., 2010; Lee, et al., 2004).
Studies have shown that caspase-3 is activated in rodent models of catabolic disease such
as diabetes. The activated caspase-3 cleaves skeletal muscle actin and this caspase-3
activation has been shown to be an initial critical steps in skeletal muscle loss (Lee, et al.,
2004; Du, et al., 2004), much like that observed in calpain coordinated protein
degradation with the ubiquitin proteasome. One last proteolytic system that also
coordinately participates with ubiquitin proteasome protein degradation is the lysosomal
pathway. Although our studies did not address the effect of PMI5011 on this group of
proteases, the lysosomal proteases also plays an important role in skeletal muscle loss
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associated with disease. Cathepsins are the major lysosomal proteases and it has been
recognized that cathepsin L is a general marker of muscle atrophy associated with disease
(Bechet, et al., 2005). Cathepsin L is induced early in catabolic states and has been found
to be upregulated in type 2 diabetes (Huang, et al., 2003). In addition, glucocorticoidinduced muscle wasting (Dardevet, et al., 1995) was associated with increased levels of
cathepsin B and D mRNA. These cathepsin proteases of the lysosome are likely act in
association with the ubiquitin proteasome system (Baracos, et al., 1995; Wing and
Goldberg, et al., 1995) in addition to caspases and calpains (Combaret et al., 1996) or
with both (Mansoor et al., 1996; Taillandier, et al., 1996) in coordinated degradation of
skeletal muscle proteins.
Due to the importance of these additionally coordinated proteolytic systems with
ubiquitin proteasome protein degradation and the evidence provided by this study that
PMI 5011 regulates non-proteasomal protein degradation, future studies with PMI 5011
should therefore seek to determine the effects of PMI 5011 on muscle-specific caspase,
calpain and cathepsin expression in association with muscle atrophy provided in these
models.
5.3 Future Studies
Studies to determine the level of CAPN3 expression in skeletal muscle of mice
supplemented with PMI 5011 could provide further insight into the effects of PMI 5011
on the coordinated regulation of calcium-dependent proteolysis and the ubiquitin
proteasome system. A possible role for the muscle-specific lysosomal Cathepsin L in
coordination with the ubiquitin-proteasome system (Huang, et al., 2003), would provide
additional information on the overarching capabilities of PMI 5011 to regulate protein
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degradation as will examination of the effect of PMI5011 on caspase activity in skeletal
muscle.
Another link to be made in future studies is through the PI3K/Akt signaling
pathway that regulates both Atrogin-1 and MuRF-1 by directly inhibiting the FoxO
transcription factors known to induce both atrogin-1 and MuRF-1 gene expression. In
Akt-dependent phosphorylation of FoxO1 or FoxO3a, both are excluded from the nucleus
where these transcription factors can no longer upregulate the transcription of atrogin-1
or MuRF-1 gene expression (Sandri, et al., 2004; Stitt, et al., 2004 and Glass, 2010). To
further understand the role of PMI 5011 in affecting FoxO3a-dependent regulation of
these two muscle-specific ligases, FoxO3a localization should be determined by cellular
fractionation followed by western blot analysis of the cytoplasmic and nuclear fractions
and by in situ immunolocalization. This will help determine if FoxO3a is indeed being
downregulated by its exclusion from the nucleus due to PMI5011.
Previous studies associated increased protein content of skeletal muscle with PMI
5011-mediated changes in insulin sensitivity (Wang, et al., 2011). We find that the
increase in protein content observed by Wang, et al., 2011, is associated with PMI 5011
inhibition of ubiquitylation as well as proteasomal and non-proteasomal activity in
skeletal muscle. However, we did not focus our efforts on the effects of PMI 5011 on
protein synthesis. Insulin is a potent anabolic hormone that not only regulates protein
degradation but also regulates protein synthesis by activating the mTOR pathway
(Miyazaki and Esser, 2009). It is therefore, feasible that PMI 5011’s insulin stimulating
activity could also play a role in protein synthesis through insulin-stimulated mTOR
signaling. Future studies on PMI 5011 in skeletal muscle could shift towards a focus on
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its effects on protein synthesis by elucidating its role in signaling pathways such as the
mTOR signaling pathway. Additionally, the translation initiation factor eIF3f is a
downstream target of Atrogin-1 (Csibi, et al., 2008; Csibi, et al., 2009; LagirandCantaloube, et al., 2008). It is possible that the observed downregulation of Atrogin-1
expression by PMI 5011 could be linked to increases in protein synthesis by inhibiting
the degradation of the initiation factor eIF3f. In addition to enhanced mTOR signaling,
this data would provide additional evidence of PMI 5011’s effects on protein synthesis.
PMI 5011’s possible role in protein synthesis would provide additional insight into its
complete contribution to overall conservation of skeletal muscle mass.
Finally, the goal in biomedical research of using medicinal plants as a source of
therapeutic agents is to target the isolation of the bioactive compounds for synthesis.
Future studies should also include bioassay guided fractionation studies to determine the
active compounds responsible for the regulation of protein degradation and muscle mass
conservation in catabolic diseases. These experiments would initially focus on regulation
of proteasome activity by subfractions of PMI 5011, including the 6-emethoxycapillarisin
and 2’, 4’ dihydroxy-4-methoxydihydrochalcone subfractions previously identified as
having anti-hyperglycemic effects (Govorko, et al., 2007).
To conclude, natural drugs from traditional medicines are again gaining
popularity due to fewer side effects, reduced cost, and increased patient use. Non-timber
forestry products provide vital plants or plant parts to be utilized for drug discovery for
the treatment of many important diseases and associated symptoms such as the muscle
atrophy caused by insulin resistance and type 2 diabetes. In addition, and important to
this author, non-timber forestry products contribute to sustainable forest management,
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conservation, and to both economical and developmental objectives (Panayotou and
Ashton, 1992). These non-timber forestry products provide dual benefits to both
biomedical research and to the renewable natural resource organizations and forests of
our Country. A proposed model of PMI 5011’s actions and testable hypotheses related
to future studies is illustrated in Figure 5.2 below.
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Figure 5.2 Proposed Model of PMI 5011 Regulation of Muscle Atrophy in Type 2
Diabetes.
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